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 I 
SOMMARIO 
 
 
Il sarcoma di Kaposi (KS) è una rara neoplasia di natura vascolare a diffusione 
multicentrica, correlata a infezione da Human Herpesvirus 8 (HHV-8). Sulla base 
delle caratteristiche clinico-patologiche, il sarcoma di Kaposi viene generalmente 
suddiviso in quattro forme: classico (cKS), epidemico (o AIDS-associato), 
endemico e iatrogeno. Sebbene sia stato ormai dimostrato come il virus HHV-8 sia 
l’agente eziologico della patologia, tuttavia è da sottolineare il fatto che l’infezione 
di tale virus è necessaria ma non sufficiente per lo sviluppo del sarcoma di Kaposi, 
e che quindi esistono altri fattori, propri del virus (modalità di trasmissione, 
potenzialità patogenica dei vari genotipi virali) o dell’ospite (predisposizione 
genetica, condizione immunologica) che possono influenzarne lo sviluppo. Le 
cellule natural-killer (NK) sono una componente fondamentale della risposta 
immune innata contro infezioni virali e come difesa per lo sviluppo di cellule 
tumorali: la loro attività è modulata da un complesso sistema basato sul legame di 
particolari recettori presenti nella loro superficie, i killer cell immunoglobulin-like 
receptor (KIR), a loro volta suddivisi in KIR attivatori e KIR inibitori, agli human 
leukocyte antigens di classe I (HLA-I), presenti sulle superficie delle cellule target. 
Sulla base di tutti questi dati, lo scopo di questa tesi di dottorato è di verificare se 
lo sviluppo del cKS e del KS epidemico sia correlato a particolari parametri virali 
del virus HHV-8 (presenza di anticorpi, carica virale, genotipo) o a un particolare 
genotipo KIR/HLA recettore/ligando dell’ospite, confrontando pazienti affetti da 
cKS e da KS epidemico con appropriati gruppi di controllo. Per quanto riguarda i 
parametri virali, gli anticorpi anti-HHV-8 sono stati trovati in tutti (100%) i pazienti 
cKS e nell’80% dei pazienti con KS epidemico, mentre erano presenti solo nel 50% 
dei soggetti di controllo HIV+ e nel 10% dei soggetti sani HIV- (p<0.0001). Inoltre, 
per quanto riguarda il diverso genotipo virale, i pazienti cKS con progressione 
rapida della malattia presentavano maggiormente il genotipo A del virus HHV-8 
(63.6% vs 23.1%), mentre quelli con progressione lenta il genotipo C (76.9% vs 
36.4%; p=0.003). Per quanto riguarda l’aspetto genetico dell’ospite, i KIR attivatori, 
assieme ai loro ligandi HLA, sono risultati più frequenti nei pazienti con cKS e KS 
epidemico rispetto ai soggetti non-KS, indipendentemente dall’infezione o meno da 
HHV-8 o da HIV. Prendendo in considerazione i geni KIR attivatori uno ad uno, il 
gene KIR2DS2 è risultato significativamente più frequente sia nei pazienti con cKS 
sia in quelli con KS epidemico rispetto ai soggetti sani (p=0.02 per entrambi), 
mentre i geni KIR2DS1 e KIR3DS1 sono stati trovati più frequentemente nei 
pazienti cKS (p=0.02 e p=0.04 rispettivamente). Inoltre, prendendo in 
considerazione il complesso KIR/HLA, il genotipo attivatore KIR2DS1/C2 è 
risultato positivamente associato con lo sviluppo di cKS (p=0.01). Nessuna 
differenza è stata invece trovata nella distribuzione dei KIR inibitori e degli HLA tra 
i gruppi presi in esame. In conclusione, questo studio dimostra che 1) il genotipo A 
del virus HHV-8 è associato ai parametri clinici peggiori della patologia, inclusa la 
sua progressione rapida, 2) nel cKS e KS epidemico è presente un “milieu” 
attivatorio KIR/HLA, e che questo milieu possa quindi essere un fattore di rischio 
per lo sviluppo della neoplasia. 
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ABSTRACT 
 
 
Kaposi’s sarcoma (KS) is a rare vascular tumor of the skin related to Human 
Herpesvirus 8 (HHV-8) infection. Based on clinical and pathological characteristics, 
KS is divided in four different forms: classic KS (cKS), epidemic (or AIDS-
associated) KS, endemic KS and iatrogenic KS. Although the link between HHV-8 
and disease has been demonstrated, it is important to note that the HHV-8 
infection is necessary but not sufficient to develop the disease: many important 
aspects remain to be elucidated, regarding both viral factors, as presence of 
antibody anti-HHV-8, viral transmission and pathogenic potential of different viral 
genotypes, and host predisposition to tumor development, different from person to 
person. Natural killer cells are central components of the innate immune response 
against viral infection and tumor growth: the modulation of their activity is a 
complex and multi factorial phenomenon triggered by the binding of inhibitory or 
activating killer cell immunoglobulin-like receptors (KIRs) to class I human 
leukocyte antigens (HLAs). For these reasons, the objective of this thesis is to 
verify whether the development of cKS and epidemic KS is related with particular 
HHV-8 viral parameters (viral load, genotype) or with particular host KIR/HLA 
receptor/ligand genotype, comparing cKS and epidemic KS patients with the 
appropriate control groups. Regarding the viral parameters, anti-HHV-8 antibodies 
were detected in all (100%) cKS patients, and in 80% of epidemic KS patients, 
whereas they are present in 50% of HIV+ healthy individuals and in 10% of HIV- 
healthy donors only (p<0.0001). Moreover, when the HHV-8 genotypes were 
analyzed, A subtype was significantly more frequently isolated in cKS patients with 
fast progression of the disease (63.6% vs 23.1%), whereas C subtype in 
individuals with slow progression (76.9% vs 36.4%; p=0.003). Regarding the host 
genetic aspects, activating KIRs, toghether with their HLA ligands, were more 
frequent in cKS and epidemic KS compared to non-KS subjects, regardless of the 
presence or absence of HHV-8 or HIV infection. Considering the activating KIR 
one by one, the KIR2DS2 gene was significantly prevalent in both cKS and 
epidemic KS patients (p=0.02 for both), whereas KIR2DS1 and KIR3DS1 genes 
were more prevalent in cKS patients (p=0.02 and p=0.04 respectively). Moreover, 
considering the KIR/HLA complexes, the activating KIR2DS1/C2 genotype was 
positively associated with cKS development (p=0.01). Finally, the inhibitory KIR 
distribution, as well as the HLA ligand distribution alone, did not reveal any 
statistical association with cKS or epidemic KS. In conclusion, this study shows 
that 1) the A genotype of HHV-8 is associated with worst clinical parameters of KS, 
including faster progression, 2) that a KIR/HLA “activating milieu” is present in cKS 
and epidemic KS and that such milieu may be a risk factor for the development of 
the tumor. 
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LIST OF SYMBOLS AND ABBREVIATIONS 
 
 
AIDS: acquired immunodeficiency syndrome 
APC: antigen-presenting cell 
Arg: arginine 
Asp: aspartic acid 
BCBL: body-cavity-based lymphoma cells 
bFGF: basic fibroblasts growth factor 
BK virus: Brennan-Krohn virus 
bp: base pairs 
CD: cluster of differentiation 
CMV: citomegalovirus 
cKS: classic Kaposi’s Sarcoma 
COX2: cytochrome oxidase subunit II 
cyc: cycline 
DC-SIGN: dendritic cell-specific ICAM-3-grabbling nonintegrin  
DMSO: dimethyl sulfoxide 
DNA: deoxyribonucleic acid 
dNTP: deoxyribonucleotide triphosphate 
DR: death receptor 
EBV: Epstein Barr virus 
EDTA: ethylenediaminetetraacetic acid 
FBS: fetal bovine serum 
FITC: fluorescein isothiocyanate 
FLADD: fas-associated protein with death domain 
FLICE: FLADD-like IL-β-converting enzyme 
FLIP: FLICE-inhibitory protein 
Gly: glycine 
GPCR: G protein-coupled receptor 
HCV: hepatitis C virus 
HHV-8: Human herpesvirus 8 
HIV: Human immunodeficiency virus 
HLA: human leukocyte antigen 
HPV: human papilloma virus 
HVS: Herpesvirus saimiri 
ICAM: intercellular adhesion molecule 
Ig: immunoglobulin 
IL: interleukin 
IFA: immunofluorescence assay 
IFN: interferon 
IRF: interferon regulatory factor 
ITAM: immunoreceptor tyrosine-based activation motifs 
ITIM: immunoreceptor tyrosine-based inhibitory motifs 
LANA: latency-associated nuclear antigen 
LCL: lymphoblastoid cell line 
LRC: leukocyte receptor complex 
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LUR: long unique region 
KIR: killer Immunoglobulin-like receptors 
KS: Kaposi’s sarcoma 
KSHV: Kaposi’s Sarcoma herpesvirus 
MCD: multicentric Castleman’s disease 
MCP: macrophage chemotactic protein 
MHC: major histocompatibility complex 
microRNA: micro ribonucleic acid 
MIP: major intrinsic protein 
mRNA: messenger ribonucleic acid 
NCAM: natural cell adhesion molecule 
NK cells: natural killer cells 
ORF: open reading frames 
PAN: polyadenylated nuclear RNA 
PBMC: peripheral blood mononuclear cells 
PBS: phosphate buffer saline 
PCR: polymerase chain reaction 
PDGF: platelet derived growth factor 
PEL: primary effusion lymphoma 
qPCR: quantitative PCR 
RAP: replication associated protein 
RBP-J: recombination signal binding protein for immunoglobulin kappa J region 
RDA: representational difference analysis 
RNA: ribonucleic acid 
RPM: revolutions per minute 
RPMI: Roswell Park Memorial Institute 
RTA: replication and transcription activator 
SEM: standard error of mean 
SOX: shutoff exonuclease 
STAT3: signal transducer and activator of transcription 3 
TBE: tris borate EDTA 
TNF: tumor necrosis factor 
TPA: tetradecanoylphorbol 13-acetate 
TR: tandem repeated 
TRAIL: tumor necrosis factor-related apoptosis inducing ligand 
TYRO: tyrosin kinase binding protein 
VEGF: vascular endothelium growth factor 
VEGFR: vascular endothelium growth factor receptor 
VR: variable region 
xCT: exchange cysteine/glutamate transporter 
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CHAPTER I 
 
 
INTRODUCTION 
 
 
1.1 Kaposi’s sarcoma 
 
 
1.1.1 General characteristics 
 
Kaposi's sarcoma (KS) was originally described in 1872 by the Hungarian 
dermatologist Moritz Kaposi as “a multiple pigmented sarcoma affecting elderly 
Mediterranean men” [1]. To date, several epidemiological forms have been 
classified. Kaposi’s sarcoma lesions are histologically complex and evolve over 
time, from a patch or plaque-like lesion at early stages to nodular lesions 
characteristic of disease progression. Several hypotheses regarding the 
pathogenesis of this vascular tumor have been suggested, including both 
infectious agents and cytokine-mediated processes. In 1994 a study by Chang and 
colleagues found a novel herpesvirus present in KS tissue [2]. This virus, called 
Human Herpesvirus 8 (HHV-8) or Kaposi’s sarcoma-associated herpesvirus 
(KSHV), is now considered the etiological factor of the disease: the infection of this 
virus is necessary to develop KS. 
 
 
1.1.2 Epidemiological forms of Kaposi's sarcoma 
 
Kaposi's sarcoma is a multifocal vascular neoplasm involving the skin, visceral 
organs and lymph nodes. The lesions are complex and contain distinctive 
proliferating cells with fusiform morphology, called spindle cells, activated 
endothelial cells and infiltrating inflammatory cells [3]. At now, based on clinical 
and pathological characteristics, KS is divided in four different forms: classic KS, 
epidemic KS, endemic KS and iatrogenic KS. 
The classic form of KS (cKS) predominantly affects elderly male patients of 
Southern European heritage [4]. The tumor is also frequently described in patients 
from Israel, mainly in the Jewish population and in other Middle Eastern countries 
[5]. Disease progression in cKS patients occurs over a period of several years. The 
cKS can be associated with other neoplasias, like Hodgkin’s linphoma or B-cell 
linphoma, due to alterations of immunological system mechanisms. The patients 
have plaques and red nodules, initially localized on legs, which can spread on 
arms and, in the 10% of cases, on internal organs [6]. 
The epidemic form of KS (or AIDS-associated KS), that affects subjects 
(predominantly adult and male) with concomitant infection of HIV-1 virus, is 
clinically the more aggressive form of KS and it is characterized by multifocal 
lesions, localized in particular on head and neck, that can spread on lymph nodes, 
causing organ dysfunction. For this form of KS, the mortality is very high [6]. 
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The endemic form of KS can be found in some equatorial countries of Africa. Here, 
KS is described in both young and elderly HIV-negative patients. The disease 
progression is more aggressive than for classical KS, in particular for children 
where lymph node involvement is common [7]. 
Finally, the incidence of this vascular tumour has increased among renal transplant 
recipients and other patients receiving immunosuppressive therapy. This form is 
known as post-transplant KS or iatrogenic Kaposi’s sarcoma [6]. 
 
 
1.1.3 Histology of Kaposi’s sarcoma 
 
Kaposi's sarcoma is characterized by bundles of spindle-shaped cells and 
endothelial-lined vascular spaces with lymphocytic infiltrates. Commonly red blood 
cells percolate in the spaces between the spindle cells [8]. These spindle cells 
produce pro-inflammatory and angiogenic factors that play an important role in the 
recruitment of additional cells to the sarcoma [9, 10]. Also, KS cells are highly 
dependent on inflammatory cytokines in culture (figure 1). This observation led to 
the hypothesis that KS pathogenesis may be influenced by inflammatory cytokines 
and angiogenic factors [11, 12]. KS is not a typical sarcoma, in that multiple lesions 
may appear simultaneously at several locations, but may disappear completely 
over time. As mentioned earlier, KS starts as a patch or plaque-like lesion at early 
stages and develops into the nodular lesions characteristic of later stage disease. 
In early stages small irregular endothelial-lined spaces, surrounded by normal 
blood vessels and inflammatory infiltrates of lymphocytes can be detected. As the 
disease progresses, the number of spindle shaped cells increases throughout the 
dermis and forms slit like vascular channels containing erythrocytes (patch stage).  
In the final, nodular stage, the lesions are characterized by sheets of spindle cells 
[6]. KS cells represent a heterogeneous population, as indicated by the variety of 
surface markers. The cells identified by histology are mainly activated endothelial 
cells mixed with fibroblasts, smooth muscle cells and cells of dentritic and 
monocytic origins [13]. 
The clonality of KS is frequently discussed, as the exact tumor cell type is 
controversial. Especially in early lesions spindle cells are a minority. Spindle cells 
are usually not prominent until late stage disease. It is demonstrated that spindle 
cells belong to an endothelium lineage that expresses the vascular endothelium 
growth factor receptor-3 (VEGFR-3), a marker of lymphatic vessels [14]. Other 
studies analyzing inactivation pattern of the X chromosome, a marker for clonality, 
revealed both a monoclonal and polyclonal pattern [15]. KS may be initially a non-
clonal proliferation, but may sometimes develop into a clonal malignancy with 
metastases during advanced disease [16]. 
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Figure 1 - Histological image of a characteristic KS lesion with hematossilin-eosin 
treatment. In particular, we can see the spindle cells, with their characteristic 
fusiform form, and the neo-angiogenesis 
 
 
1.1.4 Pathogenesis of Kaposi’s sarcoma 
 
Kaposi's sarcoma lesions produce high levels of cytokines both in vivo and in 
culture. Several cytokines and growth factors have been implicated in the 
proliferation of KS spindle cells, including oncostatin M, platelet derived growth 
factor (PDGF), Interleukin-1ß (IL-1 ß), IL-6, IL-8, basic fibroblasts growth factor 
(bFGF), VEGF, macrophage chemotactic protein-I (MCP-I), and the HIV-1 Tat 
protein [9,11,17]. Data from gene expression studies further support their 
involvement in KS pathogenesis as angiogenic properties of IL-6, bFGF and IFN-γ 
(interferon gamma) could be demonstrated in vitro [18]. As disease progression in 
epidemic KS is more aggressive, it has been suggested that proteins encoded by 
HIV may influence tumour growth. Observations showed that the transcription 
activator protein, Tat, in combination with bFGF, stimulates the proliferation of KS 
associated spindle cells in vitro and can induce KS-like lesions in mice [19]. This 
HIV encoded protein also induces cellular genes that are pro-proliferative and pro-
inflammatory (MCP-1, IL-6) in KS and possibly enhance the recruitment of 
leukocytes to KS lesions [20]. While in vitro and animal models strongly suggested 
that cytokines and growth factors play an important role in the development of KS 
[19], epidemiological data implicated a sexually transmitted cofactor [6]. AIDS 
patients with Kaposi's sarcoma are predominantly gay or bisexual men, rather than 
patients who acquired the virus through heterosexual contact, haemophiliacs or 
intravenous drug users [6]. These findings favour an infectious agent or co-factor in 
the development of KS. Infectious agents such as cytomegalovirus (CMV), HHV-6, 
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Human Papilloma Virus (HPV), BK virus and other viral or bacterial pathogens 
have all been linked to KS. However, in 1994 a research group in New York 
detected herpesvirus-like DNA from biopsies of epidemic KS using a subtractive 
DNA hybridisation technique known as representational difference analysis (RDA) 
[2]. The technique relies on cycles of subtractive hybridisation and polymerase 
chain reaction to enrich and isolate nucleotide sequences which differ between KS 
affected tissue and unaffected surrounding cells. Two subgenomic BamHl 
fragments of DNA, designated KS33OBam and KS631Bfl were isolated. Subsequent 
computer-assisted homology searches revealed that these novel sequences were 
related to the minor capsid and tegument protein genes of the lymphotropic 
gamma-herpesviruses Epstein Barr (EBV) and Herpesvirus saimiri (HVS) [2]. 
Further characterization of this newly identified the agent, called Human 
Herpesvirus 8 (HHV-8), and the sequencing of its whole genome [21] confirmed its 
classification as a member of the gamma-2 herpesvirus family [22]. Visualization of 
herpesvirus like particles by electron microscopy provided additional evidence for 
the viral origin of these sequences [23]. 
 
 
1.2 Human Herpesvirus 8 (HHV-8) 
 
 
1.2.1 General characteristics 
 
Human Herpesvirus 8 (HHV-8), also known as Kaposi’s sarcoma-associated 
Herpesvirus (KSHV), belongs to viral Herpesviridae family, Gammaherpesvirinae 
subfamily, Rhadinovirus genus [22]. 
 
 
1.2.2 Epidemiology of HHV-8 
 
Polymerase chain reaction and serological studies have been used to define the 
epidemiology of HHV-8. Current knowledge suggests that HHV-8 is not ubiquitous 
in Northern Europe, North America and some parts of Asia, but is relatively 
common in Mediterranean country (Italy, Greece, Israel) and Africa [24]. In the 
general population of North America, Japan and Western Europe, HHV-8 
seroprevalence in blood donors may be no greater than 1% (figure 2) [25]. In 
contrast, the seroprevalence of HHV-8 is higher in some populations at risk for 
sexually transmitted diseases, with the highest prevalence in homosexual male 
groups. Among HIV infected individuals, antibodies against the HHV-8 LANA 
(latency-associated nuclear antigen) protein can frequently be detected in 
homosexual patients (35%) as well as in 70-85% of HIV infected patients with KS. 
Furthermore patients who reported homosexual intercourse with other males have 
significantly elevated risks for KS, both in Europe and in North America [26]. In 
contrast, groups with low risk for the development of KS (blood donors, HIV 
positive women, intravenous drug users and haemophiliacs) show correspondingly 
low rates of seropositivity (1-3%) [27].  
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Figure 2 - HHV-8 seroprevalence in the world 
 
 
Conversely, in Mediterranean Europe the virus is relatively abundant in the general 
population, reflecting the higher incidence of classic KS (up to 20% in south 
Greece and in some regions of Italy) [28]. In particular, in Italy the HHV-8 
seroprevalence is relatively low in the North (5-7%), medium in the Centre (7-9%), 
and high in the South (23-27% with hotspot in Sicily and Sardinia). To note, in the 
North there are some hotspots, as along the Po river, in which the seroprevalence 
can reach the (figure 3) [24, 29]. Also in semen samples from Italian semen donors 
the prevalence of HHV-8 is high (13-23%) [30]. In Africa and the Middle East 
infection without disease is widespread, up to 60% seropositivity [31]. The 
transmission route of HHV-8 is different in Africa compared to Northern Europe 
and the US. While in Northern Europe HHV-8 is more likely to be acquired through 
sexual contact after puberty [32], in Africa, HHV-8 seropositivity is common among 
children from East and South Africa [33]. Since the AIDS epidemic, the incidence 
of KS has risen explosively. KS is now the most frequently reported tumor in 
several African countries, especially in Uganda, where childhood KS has risen 
more than 40 fold [7]. 
 
 
 
 
 
 
 8 
 
 
Figure 3 - HHV-8 seroprevalence in Italy 
 
 
Studies suggest that vertical as well as horizontal transmission among children in 
Africa may play an important role in the route of infection [34]. Usually the mother 
of an HHV-8 positive child will be positive as well. How the virus is transmitted to 
children is unknown (possibly during child birth or breast feeding). It has been 
shown that saliva from PCR positive samples may contain infectious virus [35]. 
However, it is to note that a recent study, published by the lab in which I perform 
my PhD thesis, showed that in Italy HHV-8 infection is greatly enhanced within 
families of classic Kaposi’s sarcoma patients, suggesting that close contact in 
general, and not only sexual contact, can contribute to the spread of the virus also 
in this KS form [36]. 
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1.2.3 Virion structure 
 
HHV-8 has morphological features typical of herpesviral capsids. Electron 
microscopy using induced Primary effusion lymphoma (PEL) cell lines revealed 
both intranuclear herpesvirus nucleocapsids and complete cytoplasmic virions. 
Capsid, 110 nm in diameter, is formed by 162 capsomeres with icosahedric 
symmetry and is surrounded by tegument and an by envelope, formed by a double 
coat of cellular lipids, associated with viral glycoprotein (figure 4). Within the 
nucleus, a nucleocapsid with an electro-dense core can be detected [37]. Studies 
on purified virions from PEL cell lines showed the presence of at least 24 virion 
proteins: 5 capsid proteins, 6 tegument proteins, 8 envelope glycoproteins and 
other 5 with not known localization. [38]. The capsid is structured by 12 pentons 
and 150 esons, formed respectively by 5 or 6 copies of the major capsid protein 
(MCP, Open Reading Frame 25, ORF-25); the capsomeres are linked by 
eterotrimerix structures formed by two different proteins, TRI-1 (ORF62) and TRI-2 
(ORF26), mixed in 1:2 ratio. 
 
 
 
 
Figure 4 - HHV-8 virion showed by A: schematic cartoon; B: electronic microscopy 
 
 
Little is known on real function of tegument viral proteins; however we can 
hypothesize that they have important regulatory function and that have a critical 
role on replication cycle. In particular, the protein encoded by ORF-45, early 
expressed in lytic viral infection, can block the innate immune response, linking the 
host protein IRF-7 (Interferon Regulator Factor 7), inhibiting the transcription of 
IFN- α (interferon alpha) and IFN-ß genes [38]. Moreover, recent studies showed 
that this protein plays a critical role in ex novo infection and also in the release of 
viral progeny from infected cells [39]. The envelope is formed by herpesviridae 
conserved gB (ORF-8), gH (ORF-22) gL (ORF-47), gM (ORF-39) and gN (ORF-53) 
glycoproteins, and by ORF-K8.1, ORF-68 and ORF-28 proteins. The protein 
encode by ORF-K8.1 causes the viral adhesion on cell surface with a eparan-
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sulfate linking, and, in vivo, stimulates the production of neutralizing antibody [40]. 
The gB protein has a site for eparan-sulfate too; moreover, in its extracellular 
domain, it has the aminoacidic motif Arg-Gly-Asp (RGD), that allows it to interact 
specifically with α3β1 integrin, essential for the virus for the penetration in the host 
cell. As other herpesviruses, gH and gL proteins formed a heterodimer: gB, gH and 
gL are important for the penetration in the host cell and, when they are expressed 
in HHV-8 infected cells, cause the polykaryocytes formation [41]. In HHV-8 virion 
some cell proteins are present, as ß-actin and the myosin-II type A heavy chain, 
suggesting a role of the cytoskeleton on viral capsid intracellular carrying on, 
assembling and coming out. [38]. Finally, more than 11 viral mRNA are 
incorporated in the particle, probably in the tegument level. The majority is 
transcripted in large quantity during the lytic cycle and so they are included 
randomly during the phase of the viral progeny building. However, one of these 
mRNA, that encodes a viral protease, normally is not transcripted in high levels, 
suggesting that probably there are specific mechanisms for the recruitment of viral 
mRNA in mature virus [42]. 
 
 
1.2.4 HHV-8 genomic organization 
 
The genomes of gammaherpesviruses exhibit a common structure. Large collinear 
genomic blocks, encoding typical herpesviral proteins (DNA polymerase, 
thymidylate kinase, capsid proteins), are interspersed by regions containing virus 
type-specific Open Reading Frames (ORFs) [43]. These unique ORFs are 
predominantly involved in physiological processes and determine the pathogenesis 
of each virus. In figure 5 a schematic picture of the HHV-8 genome is shown. The 
complete sequence of virus has been determined from a PEL derived cell line, BC-
1 [21] as well as from a KS biopsy specimen [44]. The genome is a 170 kb double 
stranded DNA molecule consisting of a central, low-GC content, long unique region 
(LUR) of 140.5 kb which is flanked each side by non coding tandemly repeated unit 
(TR). Each repeat is approximately 800 bp in size and high in GC content (85%) 
[45]. The genomic organization of HHV-8 is very similar to other Rhadinoviruses 
[46]. Within the LUR, 89 ORFs have been identified: 66 of them have sequence 
similarity to Herpes Virus Saimiri (HVS) ORFs, and for this reason the 
nomenclature for individual genes correspond to the HVS genome. 
HHV-8 shares the genomic block organization of other herpesviruses. In HHV-8 
the conserved genes are arranged in four or five blocks and include major 
structural proteins, DNA synthetic enzymes, glycoproteins and a viral proteinase 
and assembly protein. These genes are required for replication and assembly of 
new virus progeny. Between these blocks are non-conserved regions that show 
homology to other Rhadinoviruses, e.g. the v-cyclin, LANA or vGPCR (viral G 
Protein Couple Receptor). In addition, 15 ORFs have been identified in HHV-8 that 
are unique and show no similarity with other known viral genes. These unique 
open reading frames have been designated with a K prefix (K1-K15). 
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Figure 5 - HHV-8 genome in circular episome form 
 
 
In the genome there are two sequences that work as origin of replication (ori) and 
they are recognized by viral DNA polymerases: the first one is between ORF-K4.2 
and ORF-K5 (left ori) and the second one is between ORF-K12 and ORF-K71 
(right ori). A general feature observed in DNA viruses is the presence of ORFs with 
significant homology to cell cycle regulatory and signaling proteins as well as 
proteins that can interfere with the immune system. These genes are mainly 
unspliced and may have been captured from the host cell during viral evolution. In 
HHV-8 this “piracy” of eukaryotic genes seems to be more extensive than is seen 
in any other herpesvirus [47]. The HHV-8 genome is equipped with several genes 
that encode proteins allowing the virus to escape cellular responses to viral 
infection. On infection, the host activates a number of anti-viral immune responses, 
including cell cycle arrest, apoptosis and mobilization of the immune system. HHV-
8 has evolved proteins that have immunomodulatory functions such as cytokines 
(vMIP-I; vMIP-II) and a homolog to human IL-6 (vIL-6) [47]. Other proteins 
deregulate cell cycle mechanisms by interfering with receptor-mediated signal 
transduction pathways, including a homolog to the GPCR (vGPCR), a homolog to 
the Interferon Regulatory Family (vIRF), and a D-type cyclin (v-cyc) [38,47,48]. 
Also some viral gene products have transforming properties, e.g. ORF-K1 and 
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kaposin (ORF-K12) [49]. In addition, ORF-73, which encodes LANA, which has 
possible cellular growth-promoting activities [50]. To effectively suppress or delay 
apoptosis, HHV-8 carries a bcl-2 homolog (v-bcl-2, ORF-16) [51] and a protein with 
anti-apoptotic function (vFLIP, ORF-K13). Also viral homologous of cellular 
complement-binding proteins CD2I/CR2 (KCP, ORF-4) and an NCAM-like 
adhesion protein (ORF-14) have been detected [21]. The plethora of possible 
interactions between these proteins makes modeling the pathogenesis of HHV-8 
problematical. Apart from the proteins that may play a role in oncogenesis, several 
other proteins have been identified within the HHV-8 genome with importance for 
viral replication. Some examples include the processivity factor-9 (ORF-59) that 
binds the viral DNA polymerase (ORF-9) to allow synthesis of extended stretches 
of DNA without dissociation from the DNA template [52] and K8.1, a positional 
analog to HVS ORF-51, which encodes a glycoprotein expressed in lytic replication 
and present at the surface of infected cells and virion particles [53]. Finally, it 
needs to note that HHV-8 also transcripts at least 12 microRNA during the latent 
phase [54]. Their function is not known yet, but probably they module the host 
gene expression, binding themselves with cellular mRNA and interfering with their 
translation, or causing their degradation [55]. 
Otherwise, during the lytic replication, the polyadenylated nuclear RNA (PAN), 1,1 
kb, is transcripted, localizing in nucleus; it represents the more abundant viral RNA 
within productively infected cells. Its function is not known yet: probably it works in 
the building of ribonucleoproteic complexes and modules processes of RNA 
splicing [56]. 
 
 
1.2.5 Variability of the genome 
 
Overall the HHV-8 genome derived from B cells or spindle cells differs only 0.4% 
from each other [46). Based on sequence comparison of ORF-K1 among different 
HHV-8 samples, five main distinct subtypes, A, B, C, D, have been described 
which differ by 15 to 30% at the aminoacid level in this gene [57], showing 
distinctive ethnic and geographic association. Moreover, the A subtype can be 
divided into five distinct subgroups, referred to as A1, A2, A3, A4, and A5 variants, 
with the A1, A2 and A4 variants separated from the A3 and A5. Also the C subtype 
can be divided in four distinct subroups, C1 and C2 (linked together), and C3 and 
C4 (linked together). Most epidemic KS cases in the United States are A1, A4 or 
C3 variants, whereas classic, iatrogenic and epidemic cases from the Middle East, 
Asia, and Europe are mostly classified as C1, C2 and C4 variants. Also the few 
cases of classic and iatrogenicic Kaposi’s sarcoma in United States are classified 
as C1, C2 and C4 variants. Examples of the B subtype were found almost 
exclusively in epidemic or endemic KS patients from Africa or of African heritage, 
whereas the rare D subtypes were found only in KS patients of Oceania or Pacific 
Island heritage [58]. Finally, other three minor HHV-8 subgroups had been 
descried: E subtype, clustering in small and isolated populations of the Brazilian 
and Equadorian Amazon regions [59, 60], Z subtype, detected in a small cohort of 
Zambian children  [61], and F subtype, identified in Ugandan Bantu tribe [62]. 
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1.2.6 HHV-8 and oncogenesis 
 
HHV-8 infection of endothelial cells, circulating endothelial or haematopoietic 
progenitors leads to changes in their morphology, glucose metabolism growth rate, 
lifespan and gene expression, resulting in the development of KS [63]. HHV-8 
oncogenicity is reflected by the numerous pro-angiogenic molecules that are 
induced after infection of endothelial cells, including members of the VEGF–
VEGFR family, angiopoietin family, cyclooxygenase 2 (COX2) and angiogenin [64]. 
However, in most experimental systems, in vitro infection of endothelial cells with 
HHV-8 leads to morphological changes and an extended lifespan and provides a 
survival advantage in response to apoptotic stimuli, but not full neoplastic 
transformation. Moreover, although HHV-8 encodes oncogenic genes that could 
potentially induce all KS-related malignant phenotypes, HHV-8 infection in the 
general population rarely leads to KS. This underscores the existence of cofactors, 
such as HIV or drug-induced immunosuppression, that are required for the virus to 
induce a tumour. 
Although the vast majority of KS spindle cells are latently infected with the virus, in 
a small proportion of infected cells the virus undergoes lytic replication leading to 
the production of mature virus and cell lysis. Apart from the v-cyclin and vFLIP, the 
other cellular orthologues that are encoded by HHV-8 are early lytic genes that are 
generally expressed only in cells in which the virus is undergoing lytic replication. 
However, certain HHV-8 immunoregulatory and growth-promoting genes, including 
vIL-6, vMIR3 and vMIR5, could be activated by Notch signaling independently of 
the lytic transactivator RTA [65]. Moreover, limiting-dilution reverse transcription-
PCR analysis shows that transcripts such as vIL-6 can be expressed in HHV-8 
latency in a context-dependent manner; for example, in B cell lines [66]. This 
implies that the expression of HHV-8 genes might not be restricted by the classic 
herpesviral paradigm of latent or lytic infection, as lytic genes can be expressed 
without the full execution of the lytic cycle. This is an important observation when 
we consider the complementary role of latent and lytic gene-expressing cells in KS 
pathogenesis. PEL cells are latently infected with HHV-8 and were instrumental in 
classifying HHV-8 genes as latent or lytic, and identifying the major effectors of 
latent and lytic replication [67]. Many observations made from PEL-derived tumors, 
such as the switch to lytic replication that occurs during in vivo growth, are also 
observed in KS models, indicating that PEL is a valid model to study aspects of 
HHV-8 biology.  
 
 
1.2.7 HHV-8 replication cycle 
 
Like every herpesvirus, the starting event of HHV-8 replication cycle is the 
attachment of the virion with cell surface, mediated by interaction of K8.1 
glycoprotein and gB with the heparan sulfate glycosamminoglycan, a molecule 
covalently linked to extracellular domains of a lot of membrane proteins. This 
interaction is not necessary for virus, but it increases the penetration efficiency, 
facilitating the interaction with specific receptors [68]. 
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At now at least three different cellular proteins that could work as HHV-8 receptors 
are identified. The virus interacts with α3ß1 integrin using an Arg-Gly-Asp motif 
present in gB protein. This integrin is expressed on many cell types susceptible to 
HHV-8 infection, as B-cells, endothelial cells, fibroblasts, and epithelial cells. 
However, although antibodies against α3ß1 integrin interfere with virus-cell 
interaction, they cause just an infection reduce (about 50-70%), but not its total 
disappear [69]. For this reason, it is clear that α3ß1 integrin cannot be the only 
host protein involved in the HHV-8 entrance. A second protein that can work as 
HHV-8 receptor is the exchange cystein/glutamate transporter (xCT), a protein that 
mediates the extracellular cystein entrance linked with glutamate exit: in fact its 
expression makes normally non-susceptible cells permissive to infection, whereas 
antibodies against xCT completely block the virus entrance [70]. In particular, this 
protein forms a heterodimer with CD98 on the surface cell and this complex 
associates itself with α3ß1 integrin: for this reason it is hypothesized that the 
integrins, ubiquitary expressed in many tissues, are not real HHV-8 receptors, but 
they are a part of a multi-protein complex that is recognized by virus and that 
mediates its entrance in target cell [70]. Finally, HHV-8 uses CD209 or DC-SIGN 
(dendritic cell-specific ICAM-3-grabbling nonintegrin) protein, a C-type lectin, as 
specific receptor for the entrance in dendritic cells and in monocytes-macrophages: 
in fact, the link of virus to these cells and infection are blocked by antibodies 
against this lectin or its solubile forms [71]. In particular, the link between DC-SIGN 
and virus seems to be because DC-SIGN recognizes specific carbohydrate motifs 
in glycoprotein of viral envelope. Dendritic cells infection is associated with a 
reduction of DC-SIGN expression, with compromise of endocytic activity and with 
inhibition of antigens presentation to CD8+ T cells, with consequent dysfunction of 
immune response [72]. So, according to all these data, it seems that HHV-8 
recognizes cellular membrane proteins that are not correlated with themselves, 
suggesting that virus uses many receptors to infect target cells, and that they are 
different for each cell type. 
The virus penetration, at least in some cell types, including B cells, fibroblasts and 
epithelial cells, happens for endocytosis of viral particle followed by fusion of 
envelope with the endosome membrane, due to drop in pH (ph-dependent 
mechanism), with the release of the capsid in cytoplasm [73]. However, according 
to the mechanisms of penetration of the other herpesviruses, it can not be 
excluded that HHV-8 can penetrate into cells through a direct fusion of viral 
envelope with plasmatic membrane (pH-independent mechanism). The fusogenic 
complex used by HHV-8 includes the gB, gH and gL glycoproteins [41]. Once 
released into the cytoplasm, capsid, probably in a similar way to Herpes simplex 
virus 1 (HSV-1), is transported through the system of microtubules to the nuclear 
membrane; here the viral DNA is released into the nucleus where it circularizes in 
episome form by action of host cell enzymes. Through interaction with cellular 
histonic proteins, the episome organizes itself into chromatin-like structures, 
becoming a substrate suitable for attachment of cellular RNA polymerase II. At this 
point, after a first phase of generalized gene expression, the virus normally enters 
in latency maintaining the expression of a limited number of viral genes (LANA, 
vCyc, vFLIP and Kaposin); only a small percentage of de novo infected cells 
(about 1-3%) spontaneously enters in lytic cycle, exactly as shown in cell culture 
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derived from PEL tumors [74]. For its functional properties, LANA protein, whose 
principal role is to bind stably the episome to cellular chromatin, may recruit some 
transcriptional repressors on the viral DNA by inhibiting the expression of the lytic 
genes and thus favoring the maintenance of the latency phase. However, the 
program of gene expression in latency does not seem to be constant: in fact, the 
viral gene encoding the homolog transcription factor IRF3 (LANA2 or vIRF3, 
encoded by ORF-K10.6/K10.5) is expressed in the PEL cells, but not in latently 
infected cells that are present in lesions of Kaposi's sarcoma [75]. The viral protein 
LANA2, together with the other viral homologs of IRF (at least three, all expressed 
as lytic genes), contributes to escape from innate immune response, by interfering 
with IFN-α and IFN-β expression and with their antiviral activity [76-78]. The 
induction of the lytic replication is controlled by the viral protein RTA (replication 
and transcription activator, ORF-50) which has a N-terminal domain for 
dimerization and for binding to DNA, and a C-terminal domain for the 
transcriptional activation [65]. The RTA protein interacts with several cellular 
transcription factors, including STAT3 and RBP-J, activating them and thereby 
promoting the expression of viral lytic genes [79]. So a cascade of events starts, 
that leads to immediate-early and early viral genes transcription, to viral genome 
replication and, finally, to late genes transcription. Many chemical agents, such as 
phorbol esters or inhibitors of histone deacetylase, work in vitro to induce lytic 
cycle, but the specific stimuli that activate this replication in host in vivo are not 
known yet. 
Most of the early genes encode enzymes (thymidine kinases, ribonucleotide 
reductases, DNA-polymerases and helicases), or accessory proteins, directly 
involved in viral genome replication. Other early proteins are involved in the 
escape of adaptive immune specific response, such as proteins MIR1 and MIR2 
(modulators of immune recognition 1 and 2, respectively encoded by ORF-K3 and 
ORF-K5), inhibition of cell proteins synthesis, such as protein SOX (shutoff 
exonuclease, encoded by ORF-37), or in modulation of signal transduction, such 
as the proteins encoded by genes ORF-K1, ORF-K15 and ORF-74. In addition, 
among early products there are at least two proteins with regulatory functions: 
MTA (mRNA accumulation transcript, encoded by ORF-57), a protein that 
promotes viral mRNA transportation from the nucleus to the cytoplasm and that 
can potentiate the transcriptional activation RTA mediated, and RAP protein 
(replication associated protein, encoded by ORF-K8), which mediates the cell cycle 
blockage in G1 to promote the viral DNA synthesis instead of the cellular DNA 
synthesis [65]. Similar to other herpesviruses, replication of HHV-8 genome begins 
with a theta origin-dependent mode, that continues with a "circle rotating" origin-
independent method, leading the formation of long spin concatamers, that, during 
the viral DNA packaging into the capsid, are cut into linear monomers. Events that 
are downstream of the viral genome replication have not been clarified at all. 
The late genes are more abundant of the other for the availability of more 
molecules of DNA template at which RNA polymerase can bind: in fact, 
transcription of most of these genes is strongly affected by viral DNA synthesis 
inhibitors, such as ganciclovir, and foscarnet. The late proteins are predominantly 
structural proteins of capsid, tegument and envelope: the high levels of 
transcription correlate with the need for large amounts of structural proteins for the 
formation of viral progeny.  
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There are still many uncertainties about the final stages of the lytic replication 
cycle. It is assumed that the packaging of the viral genome in the new assembled 
capsid occurs in the nucleus and that, finally, the particle acquires tegument and 
envelope containing the viral glycoproteins by budding through the inner nuclear 
membrane. Then, the new viral particles would be transported by transcytosis in 
vesicles through the endoplasmic reticulum and the Golgi apparatus tanks, where 
the maturation of viral glycoproteins is completed. Finally, after vesicles fusion with 
the plasma membrane, the mature virion would be released outside the cell by 
exocytosis, leading the cell to death. Alternatively, the virus particle could lose the 
envelope during fusion with the outer nuclear membrane and acquire the final one 
by budding through the Golgi apparatus [65]. As for other herpesviruses, gB 
protein appears essential not only for binding to the target cell and the penetration, 
but also in the assembly phase, and in leakage of the viral progeny, since it has 
been shown as the deletion of the gB inhibits the release of new virions from 
infected cells [80]. A schematic picture of HHV-8 replicative cycle is represented by 
figure 6. 
 
 
1.2.8 Detection of the HHV-8 genome in Kaposi’s sarcoma 
 
Since its first description in 1994, HHV-8 DNA sequences have been detected by 
PCR in all epidemiological forms of the disease, in both fresh biopsies and in the 
vast majority of paraffin embedded material [81]. By using in-situ PCR, HHV-8 can 
be detected in all stages of the disease from early patches to nodular lesions [82]. 
In KS lesions, HHV-8 sequences have been localized to spindle and endothelial 
cells and to monocytes. Before the extensive spindle cell formation, herpesviral 
sequences are limited to the flat endothelial cells of the lesion [83]. The viral 
genome is maintained as an episome and at least one copy for cell can be 
detected [84]. The majority of spindle cells seem to be latently infected, with a 
subpopulation supporting lytic replication [85]. Several attempts to establish an in 
vitro culture system for HHV-8 using spindle cells isolated from KS have been 
unsuccessful. Spindle cells have a limited life in tissue culture and even well 
established KS cells lose the viral genome upon passage [86]. Also non-involved 
tissue from KS patients, including skin, lymphoid tissue, prostate, semen, saliva 
and PBMC, has been shown to harbor HHV-8 DNA [87].  
Furthermore, in-situ hybridization to detect the minor capsid protein mRNA showed 
that monocytic cells are productively infected with HHV-8. However, not all 
monocytes stained positive and therefore transmission of virus from spindle cells to 
monocytes was thought to be rather unlikely [88]. It has also been demonstrated 
that the virus replicates in PBMCs of KS patients [84]. PCR studies of PBMCs from 
healthy individuals have found the virus to be uncommon [31]. In contrast in areas 
at high risk for KS, HHV-8 has been detected at a high frequency [89]. It has also 
been demonstrated that the detection of KSHV in the peripheral blood of HIV 
infected patients precedes KS development and is strongly correlated with 
increased KS risk [25]. 
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Figure 6 - HHV-8 replicative cycle (latent and lytic cycle) 
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1.2.9 HHV-8 and other lymphoproliferative diseases 
 
Besides KS, HHV-8 sequences have also been associated with other 
lymphoproliferative disorders and multiple myeloma. Viral sequences have been 
consistently found in Primary Effusion Lymphoma (PEL) and Multicentric 
Castleman's Disease (MCD) [90, 91].  
 
Primary effusion lymphoma (PEL), also called body cavity based lymphoma 
(BCBL), is a rare form of AIDS-associated B cell lymphoma and was initially 
recognized in HIV infected individuals [92]. It is seen predominantly in patients with 
advanced stages of immunosupression but also cases in HIV negative patients 
have been reported. The lymphoma is characterized by malignant effusion in 
pleural and abdominal cavities, usually without significant tumor mass or 
lymphadenopathy [93]. Tumor cells are derived from a B cell lineage, as indicated 
by clonal immunoglobulin rearrangements and plasma differentiation markers. The 
majority of cells are co-infected with EBV and HHV-8 [94]. However, some cases 
have been reported where only HHV-8 is present [95]. Compared to the endothelial 
and spindle cells in KS lesions, HHV-8 DNA sequences have been reported to be 
50 times more abundant in PEL tumor cell lines [91]. Analyses showed that PEL 
cells are infected with multiple episomal copies of HHV-8, 50 to 150 copies per cell 
were detected, whereas KS cells may contain less than one copy per cell [91]. 
Several B cell lines have been established from PEL patients and from the 
peripheral blood of PEL patients to study the pathogenesis of HHV-8 as well as to 
perform sero-epidemiological studies. It is likely that these B cells may be similar to 
EBV transformed lymphoblastoid cell lines (LCL) and produce antibodies. The 
majority of these B cells are latently infected with HHV-8, with approximately 2% of 
cells spontaneously entering the lytic replication cycle to produce infectious virions 
[96]. Several research groups showed  that the addition of phorbol ester or sodium 
butyrate to HHV-8-infected PEL cell lines leads to the activation of viral gene 
expression [97]. As shown by Miller and colleagues in dually infected PEL cells 
(here the BC-I cell line), the replication of each virus can be differentially induced 
by chemicals such as TPA (EBV) or n-butyrate (HHV-8) [96]. 
 
Multicentric Castelman Disease (MCD), also called multicentric angiofollicular 
hyperplasia, is an atypical lymphoproliferative disorder described by Castelman in 
1956 [98]. The disease is characterized by generalized lymphadenopathy and 
immunological abnormalities. 
Two histological forms can be distinguished: the hyaline-vascular variant and the 
plasma variant. Patients with MCD tend also to develop non-Hodgkin's lymphoma 
or KS. The factors involved in MCD development have not yet been established. 
However, high levels of IL-6 have been found and suggested to play an important 
role in disease development [99]. HHV-8 has been detected in 50% of the plasma 
variant when HIV-infected, but HIV-negative cases have been reported [100]. In 
particular PBMCs from MCD patients have been shown to harbour the virus. 
Recently, large immunoblastic cells belonging to the B-cell lineage have been 
found to harbor the viral latent nuclear antigen (LANA) [82]. 
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1.3 Natural killer cells and KIR receptors 
 
 
1.3.1 General characteristics 
 
Natural killer (NK) cells are recognized as a population of large granular 
lymphocytes in the 1970s because of their capacity to lyse spontaneously certain 
tumor cells (figure 7) [101]. NK cells are distinguished from B and T cells as they 
lack antigen-specific receptors. NK cells play an important role in early host 
defense against viral, bacterial, and other infections as well as tumors. NK cells 
exert their effector function by killing target cells without prior sensitization and 
producing immunoregulatory cytokines and chemokines. In human, NK cells 
account for ~5-15% of circulating lymphocytes and phenotypically they are 
characterized for the expression of CD56 and CD16 surface antigens, and for the 
absence of CD3 co-receptor. CD56 antigen, an isoform of the neuronal cell 
adhesion molecule NCAM, mediates the interaction between NK cell and target 
cell, whereas CD16 is a low affinity co-receptor for Fc portion of G 
immunoglobulins, and it is involved in antibody-mediated cell cytoxicity [102]. 
Depending on CD56 and CD16 surface density, NK cells are divided into 2 sub-
populations: NK cells with low CD56 density (CD56dim) and high CD16 density, that 
are about 90% of total NK cells, and NK with high CD56 density (CD56bright), and 
low or negative CD16 expression, that are about 10%.  
 
 
 
 
 
Figure 7 - (A) Natural killer cell (on the left) that attacks and destroys a tumoral cell 
(electronic microscopy). (B) Three-dimensional elaboration of a natural killer cell, 
by the scientific journal Science 
[http://www.sciencephoto.com/media/143133/enlarge] 
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The CD56dim cells mainly carry out a cytotoxic activity, whereas the CD56bright 
mainly secrete cytokines [102]. The NK cells constitutively express receptors with 
medium and high affinity for IL-2, a cytokine that induces the CD56bright proliferation 
and increases the CD56dim cytolytic activity [102]. 
Recently, NK cells have been further divided into three subsets on the basis of 
their cytokine production profiles: NK1 cells producing type 1 cytokine IFN-γ; NK2 
cells producing type 2 cytokines IL-5 and IL-13 but not IL-4; and NK3 cells 
producing TGF-β and IL-10 [103, 104]. In general, NK cells use three different 
mechanisms to lyse target cells including perforin- FasL- and TRAIL-mediated 
cytotoxicity. Unstimulated NK cells lyse targets primarily through the calcium-
dependent release of granules containing perforin, which forms pores in target 
cells [105, 106]. In addition, the release of granules of granzyme A and B further 
enhances cell damage by DNA fragmentation [107]. Upon activation, NK cells 
release FasL stored within secretory lysosomes to the cell surface at functional 
levels and induce apoptosis in Fas+ cells. TRAIL is also expressed on NK cells 
even without activation and can induce apoptosis in cells that express TRAIL 
receptors, including death receptor 4 (DR4) and death receptor 5 (DR5) [105]. 
 
 
1.3.2 Natural killer cells development 
 
NK cells are generated from lymphoid precursors and their complete functional and 
phenotypic maturation is in bone-marrow. The stroma produces the FL and FK 
growth factors, which cause the transformation of the original progenitor in 
intermediate precursor, and IL-15, cytokine that induces the differentiation of 
intermediate precursor in a functional CD56bright NK cells [102]. The CD56dim origin 
is not known yet: somebody hypothesizes the presence of an alternative unknown 
precursor, others suggest the same precursor stimulated by different factors, 
others speculate that they derive from CD56bright cells. After the release from bone-
marrow, the majority of NK cells goes to peripheral blood or to spleen; just very few 
are in thymus and in lymph nodes [108]. 
 
 
1.3.3 Role of natural killer cells in immunity 
 
Increasing evidence has revealed the diverse effects and complicated role of NK 
cells in innate and adaptive immunity and autoimmune diseases and as NK cells 
can exert direct killing on target cells, produce immunoregulatory cytokines and 
chemokines, and interact with various immune cells [109]. 
 
 
1.3.3.1 Natural killer cells in innate immunity 
 
NK cells play a critical role in innate immune responses against infection, in 
particular in anti-viral immunity. NK cells contribute to anti-viral defenses by direct 
killing of virus-infected cells and by the production of cytokines that control viral 
replication [102, 110]. Many viruses develop strategies to escape recognition by 
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cells of the adaptive immune system, for example reducing expression of HLA 
molecules on the infected cell surface to block antigen presentation to T cells. 
Therefore, these infected cells become susceptible to NK cells lysis as they cannot 
engage inhibitory receptors on NK cells. However, some viruses have also evolved 
a number of strategies to evade NK cells, which include the expression of HLA 
decoy molecules that can legate KIR, inducing NK cell inhibition and 
downregulation of NK cell-activating ligands [111, 112]. In addition to viral infection, 
NK cells also combat other types of infections including those caused by 
intracellular bacteria, fungi and protozoa [113]. Another important function of NK 
cells is to eliminate tumor cells. Many malignant cells downregulate HLA 
expression thus rendering them susceptible to NK cell-mediated lysis [114]. NK 
cells kill malignant cells through the release of perforin and granzymes and binding 
of the death receptors Fas and TRAIL-R on target cells [105, 106]. It is realized 
that although some tumor cells do not express Fas, NK cells can induce Fas 
expression on these targets by releasing IFN-γ and so kill them by binding to the 
newly expressed Fas [106]. 
 
 
1.3.3.2 Natural killer cells in adaptive immunity 
 
NK cells can shape adaptive immune responses by regulating antigen presenting 
cells (APC), which are responsible for taking up, processing and presenting 
antigens to naive T lymphocytes. Previous studies have demonstrated that NK 
cells can modulate dendritic cells maturation by secreting cytokines, whereas NK 
cells are activated by cytokines produced from mature dendritic cells [115, 116]. 
Reciprocal interactions between NK cells and dendritic cells may represent a key 
mechanism to bridge innate and adaptive responses as this affects both the 
magnitude and polarization of T cell responses [117]. Secondary lymphoid organs 
such as spleen and lymph node and inflamed tissues have been recognized as the 
site for NK – dendritic cells interaction for the co-localization of NK cells and 
dendritic cells have been observed in the sites [118]. Apart from lymphocyte 
priming, NK cells may also provide immunoregulatory functions on downstream 
adaptive responses. NK cells can directly stimulate and inhibit T cells. Some 
studies in vitro have demonstrated that NK cells can stimulate T cell proliferation 
and cytokine production through cell-cell interaction and cytokine secretion, while 
others have indicated suppressive role of NK cells on T cells mediated by direct 
killing and cell cycle inhibition [119, 120]. In some experimental studies, NK cell 
depletion revealed this dual roles of NK cells in autoimmune diseases: NK cells 
can either promote or suppress autoimmunity by regulating autoreactive T cells 
[121, 122]. In addition to regulating T cell responses, NK cells also play a role in 
regulating B cell responses. At first, NK cells can suppress B cell responses 
through direct effects on T cells [123]. Moreover, other studies indicated that NK 
cells, instead of direct lysis, could influence antibody production and isotype 
switching of B cells through cell-cell interaction and IFN-γ [124, 125]. 
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1.3.4 Natural killer cell receptors 
 
NK cells express many types of receptors, that can be divided in activating or 
inhibitory receptors, according to their effect on NK cells cytotoxic activity. These 
receptors are usually divided in two groups: 
 
• Killer Immunoglobulin-like Receptors (KIR) 
• Heterodimeric receptors with extracellular C-type lectinic domain, like 
CD94/NKG2 and Ly49. 
 
All these receptors have class I MHC (MHC-I) molecules like ligands. In humans, 
the HLA-A, -B and –C antigens are constitutively expressed in almost every 
nucleate cells, even if with different intensity [126]. In 1990, by using a tumoral 
model, Ljunggren and Karre [127] showed, in vitro and in vivo, that NK cells are 
activated by the self-antigen MHC-I loss on the target cell. This observation leads 
to the drafting of the “missing self” hypothesis: the loss of MHC-I on the target cell 
removes the inhibitory signal on the NK cells cytotoxic activity. So, recognizing 
MHC-I, the inhibitory receptors allow the self-tolerance and the non-self aggression 
by NK cells (figure 8) [128]. 
 
Recently others receptors are identified on NK cells surface, called natural 
cytoxicity receptors (NKp46, NKp30, NK44) and co-receptors that recognize non-
MHC molecules that are over-expressed or de novo expressed in cells 
characterized by stress, cellular activation, viral infection or tumoral transformation 
(for example, MICA, MICB, Rae-1 and ULBPs molecules) [129]. 
 
 
1.3.5 Killer Immunoglobulin-like Receptors (KIR) 
 
KIR receptors are single-chain regulatory glycoproteins, belonging to 
immunoglobulin super-family, expressed on NK surface and can modulate their 
cytolytic activity. All of these receptors can recognize a particular HLA-I molecules 
set (see paragraph 1.3.14) [130]. Their molecular typing showed that molecules 
encodes by different mRNA can have the same allelic specificity, but opposite 
reactivity. 
This phenomenon was explained by the discovery that a lot of KIR are homolog 
each other for extra-cellular domain, responsible for HLA recognition, but they 
differ for transmembrane and cytplasmatic domains [131]. 
The KIR distribution in a unique NK cell population of the same subject is very 
heterogeneous [132]. KIR genes are not necessarily expressed in every NK cells 
and so every cell has a specific KIR phenotype. However, when a cell starts to 
express a particular combination of KIR genes, this expression pattern remains 
stable during the time-life as well as during the cellular division [133]. 
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Figure 8 - NK cells activation according to “missing self” hypothesis [128] 
 
 
1.3.6 Role of KIR on natural killer cells 
 
KIR receptors are divided in two groups according to their function on NK cells: 
inhibitory KIR, if they inhibit the NK cytolytic activity, or activating KIR, if they 
activate it. 
 
 
1.3.6.1 Inhibitory KIR 
 
The main function of this type of KIR is to protect self-cells from autologous attack 
by NK cells, recognizing the self-MHC-I of target cells, and blocking the cytolytic 
activating signaling of NK cells. In the case of downregulation or of absence of 
autologous HLA, due to viral infection or neoplastic transformation, these receptors 
are not longer able to mediate their inhibitory signaling and so the targeting cells 
can become susceptible to lysis by NK cells [134]. 
 
 
1.3.6.2 Activating KIR 
 
This receptors stimulate the NK cells cytolytic activity and their production of 
cytokines. Their role is not completely known yet, especially since in the same cells 
can be KIR couples with opposite activity. These receptors recognize their ligand 
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with lower affinity than the corresponding inhibitory KIR and so it is hypothesized 
that their stimulating activity on NK cytotoxicity and on cytokine production can 
happen only when, in the same time, the inhibitory signaling is down-regulated, 
going under a fixed critical value. Probably this mechanism is important to ensure a 
prevalence of inhibitory signaling to activating one, when a single NK cells express 
both the two types of receptors [134]. In particular, if at the same time a particular 
NK cell express either activating and inhibitory receptors with different HLA 
specificity, activating KIR works only if the target cell selectively looses every HLA 
allele recognized by inhibitory KIR. This mechanism is already demonstrated in 
some tumor and viral infection [135]. To note, the activating signal can be 
predominantly even if the activating KIR are over-expressed, neutralizing the 
inhibitory signal [135]. 
 
 
1.3.7 KIR nomenclature 
 
The KIR nomenclature is based on protein structure and consists of four major 
divisions according to two characteristics: 
 
- the number of extra-cellular domains (2D or 3D) 
- the length of cytoplasmatic domain (L or S) 
 
 
In particular, if they have respectively 2 or 3 extra-cellular immunoglobulin-like 
domains, KIR genes are defined with 2D or 3D suffix. The L (long) or S (short) 
letters indicate if the receptors have a long (L) intra-cellular domain, containing two 
ITIM (immunoreceptor tyrosine-based inhibitory motifs) domains, that inhibits the 
NK cytotoxic activity, or a short (S) intra-cellular domain, containing a ITAM 
(immunoreceptor tyrosine-based activation motifs) domain, that stimulates the NK 
cytolytic activity [136]. The unique exception of this rule is KIR2DL4 that, even if it 
has a long intra-cellular domain, mediates an activating signaling by the interaction 
with the accessory protein TYRO (tyrosin kinase binding protein). Moreover, this 
KIR receptor seems to be the only not to have a corresponding KIR with short 
intra-cellular domain and, unlike the others, it doesn’t have a clonal distribution, but 
it is expressed in almost the totally of NK cells [131, 137, 138]. Finally, in the KIR 
name the number that follows the L or S letter identifies each gene or molecule, 
whereas the numbers following the star key characterize the allele. 
Two pseudogenes KIR are identified too: KIR2DP1, similar to two domain genes, 
and KIR3DP1: similar to KIR3DL3, it seems to represent an ancestral KIR gene 
[139]. The KIR nomenclature is visualized with a picture by figure 9. 
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Figure 9 - Scheme of the KIR nomenclature 
 
 
1.3.8 KIR genomic region 
 
The KIR locus is polymorphic and is located on the short arm of chromosome 19 
(19q13.4) as part of the (LRC) Leukocyte Receptor Complex [140]. The probability 
of two individuals inheriting the same KIR genotype is slow, and the expression 
varying clonally adds another layer of complexity. Arrayed in a head-to-tail mode, 
KIR genes stretch over a 150 kb domain of DNA with each gene being 
approximately 10 to16 kb in length [141]. Separation between all loci approximates 
a 2 kb stretch of DNA with the exception of a 14 kb sequence upstream from 2DS4 
[142] (figure 10). Once a NK cell has committed to expressing a particular 
combination of KIR genes, that pattern remains stable through time and cell 
division [131]. 
 
 
1.3.9 KIR gene structure 
 
KIR genes are formed by 9 exons with a very high structure nucleotidic homology 
among each other (more than 98%). Exons 1 and 2 encode for the recognizing 
domain; exons 3, 4 and 5 encode respectively for the extra-cellular domain D0, D1 
and D2; exon 6 encodes for a structural extracellular portion; exon 7 encodes for 
transmembrane domain, and finally exons 8 and 9 encode the intracellular domain. 
The structure of 3D genes is formed by every exons, whereas the structure of 2D 
genes is formed by exons 1, 2, 4-9: a mutation localized on the third exon caused 
the blocking of the D0 transcription. The situation for KIR2DL4, 2DL5A and 2DL5B 
is different, because they are encoded by all exons with exception of exon 4, with 
the lacking of D1 domain. These KIR2DL genes are called type II KIR2DL, 
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whereas the others, activating or inhibitory, that have D0 domain, are called type I 
KIR2D (figure 11). 
Finally, in KIR2DP1 pseudogene exon 3 is not encoded, causing a stop codon on 
exon 4, whereas in the KIR3DP1 there is a deletion on exon 2 (figure 11) [143, 
144]. 
 
 
 
 
 
Figure 10 - Genomic organization of LRC and of a particular haplotype KIR 
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1.3.10 KIR haplotypes 
 
Extensive variation has been shown in the number and type of KIR genes present 
within individuals. Both the number and the organized arrangement of inhibitory 
and activating KIR genes determine the particular haplotype. Over 100 different 
KIR haplotype profiles were described thus far and this number keeps expanding 
as new haplotypes are discovered [139, 143]. Dependent on the KIR genes 
present, two major haplotypes are formed, namely A and B (figure 12) [141]. 
 
 
 
 
Figure 11 - KIR gene structure 
 
 
1.3.10.1 A haplotype  
 
A haplotype is relatively simple, conserved and consists of a fixed number of 
genes (figure 12). It is composed, from centromere to telomere, by KIR3DL3, 
2DL3, 2DL1, 2DL4, 3DL1, 2DS4 and 3DL2 genes. The A haplotype is more 
frequent in Caucasian and Japanese populations with a total frequency of 86 %, 
where homozygous individuals for the A haplotype make up nearly 50 % of these 
populations [141, 143]. Important characteristic of this haplotypes is that has only 
two activating KIR: KIR2DS4 and KIR2DL4. Moreover, it is demonstrated that the 
standard typing for KIR2DS4 gene can’t discriminate the entire gene from its 
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common variant, equal to KIR2DS4 but with deletion of 22 bases on the sequence 
coding the immunoglobulin domain [139]. This deletion causes the interruption for 
the translation and the premature stopping on the transmembrana domain. The 
function of this variant of 2DS4, named KIR1D, is not known yet, but its protein 
structure seems not to be compatible with an activating activity. With the 
identification of KIR1D, the A haplotypes can be divided in 2 new haplotypes, the 
A-1D and the A-2DS4 haplotype: the first one is present in the 38% of Caucasian 
population, the second in the 11,8% [139]. The A-1D haplotype identification is 
very important, because it indicates that the more frequent haplotype in Caucasian 
population has only one activating KIR, the KIR2DL4. 
 
 
1.3.10.2 B haplotype 
 
B haplotype is more variable comparing to A haplotype, comprising more activating 
KIR genes, with gene number varying greatly from haplotype to haplotype (figure 
12) [144]. Different criteria have been used for the assignment of the two 
haplotypes: while inclusion of 2DL1 and 2DL3 has been nominated A haplotypes, 
the absence of both 2DL1 and 2DL3 which has been nominated B haplotypes 
[139, 145]. The B haplotype dominates in Australian Aborigens with a frequency of 
90 % [146], while it has similar frequency to A haplotype in Caucasian population. 
Among the B haplotype’s gene, KIR2DL5 is relatively new, and it is divided in one 
expressed variant (KIR2DL5A) and one non-expressed variant (KIR2DL5B) [147]. 
The particularity of this gene is that these two variants don’t act like allele, even if 
they are. In fact they are not in the same locus, and they can be found at the same 
time in the same haplotypes in two different positions. So, with their discovery, we 
can find up to 14 different loci in the same haplotypes. 
 
 
 
 
Figure 12 - A and B haplotypes 
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1.3.11 KIR gene polymorphisms 
 
The characteristic that mainly contributes to the variability of KIR genomic region is 
its genetic polymorphism, due above all to two mechanisms: point mutations and 
the homologous recombination [145]. KIR polymorphism is similar to MHC 
polymorphism, even if lower, maybe because of the minor number of KIR genes. 
Demonstrating this high allelic polymorphism of this region, genotyping studies 
distinguished, in just four loci (KIR2DL1, 2DL3, 3DL1 and 3DL2) 22 different A 
haplotypes, underlining that less of 0,24% of unrelated by kinship can have the 
identical genotype [145]. 
 
 
1.3.12 KIR receptor expression 
 
Human NK clones express different number and combination of KIR receptors 
[132]. The only requirement for each NK clone with lytic activity is that expresses at 
least one inhibitory receptor with specificity for a self-MHC-I molecule [132]. The 
inhibitory receptor can belong to either the KIR or CD94/NKG2 family. The range of 
different KIR receptors expressed by the repertoire of NK clones is primarily 
determined by the KIR genotype, but the individual HLA genotype determines 
which KIR can be expressed as the only inhibitory receptor on individual NK cell 
clones [141]. Receptor selection occurs during NK cell development to ensure only 
NK cells with an inhibitory receptor for a self-ligand are permitted to become armed 
for cytotoxicity. Thus lytic NK cells without an inhibitory receptor for self-HLA class 
I do not appear in peripheral circulation [132, 141]. 
 
 
1.3.13 KIR protein structure 
 
KIR proteins have characteristic Ig-like domains on their extracellular regions, 
which in some KIR proteins are involved in HLA class I ligand binding. They also 
have transmembrane and cytoplasmatic regions which are functionally relevant as 
they define the type of signal which is transduced to the NK cell. KIR proteins can 
have two or three Ig-like domains (hence KIR2D or KIR3D) as well as short or long 
cytoplasmatic tails (represented as KIR2DS or KIR2DL). Long cytoplasmatic tails 
contain two ITIM domains whereas short cytoplasmatic tails contain one ITAM 
domain. Exception to this is KIR2DL4, which contains only one N-terminus ITIM.  
KIR proteins vary in length from 306 to 456 amino acid residues. Although the 
differences in protein length are mostly the consequence of the number of Ig-like 
domains present, cytoplasmatic region length diversity is also an influencing factor. 
The leader peptide of most KIR proteins is 21 amino acid residues long. However, 
the presence of a different initiation codon generates a correspondingly longer 
leader peptide in KIR2DL4 proteins. The D0 Ig-like domain present in type II 
KIR2D proteins and KIR3D proteins, is approximately 96 amino acid residues in 
length. The D1 domain of type I KIR2D and of KIR3D proteins is 102 aminoacid 
residues long, while the D2 domain of all KIR proteins is 98 aminoacid residues 
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long. The length of the stem region varies from the 24 amino acid residues present 
in most KIR proteins, to only seven amino acid residues in the divergent KIR3DL3 
protein. The transmembrane region is 20 amino acid residues long for most KIR 
proteins, but one residue shorter on KIR2DL1 and KIR2DL2 proteins as a result of 
a three base pair deletion in exon 7. Finally, the cytoplasmatic region of KIR 
proteins exhibits greater length variations, ranging from 23 amino acid residues in 
some KIR3DS1 alleles to the 96 amino acid residues present in KIR3DL2 proteins 
(figure 13) [148]. 
 
 
 
 
Figure 13 - KIR protein structure 
 
 
1.3.14 KIR ligands 
 
KIR receptors interact with the classical class I of Human Leucoyte Antigen (HLA-I) 
molecules. HLA is the human form of Major Histocompatability Complex (MHC) 
and its gene group on chromosome 6 (6p21.3) encodes for three classes of 
molecules. HLA class-I has a heavy chain 44KDa polypeptide molecule consisting 
of three globular helical domains (α1, α2, and α3) which are expressed on the cell 
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surface and which inserts into the cytosol through the cell membrane. Its heavy 
chain is always associated with a lighter β2microglobulin (β2m) chain and three 
different class I antigens (-A, -B and -C) are expressed; each of which displays 
marked allelic variation between individuals. HLA class I is virtually expressed on 
all cells and is responsible for the presentation of intracellular peptides associated 
with abnormal cellular conditions (figure 14) [149]. 
 
 
Figure 14 - Class I and class II HLA protein structure 
 
 
Like HLA-I molecules, class II (HLA-II) molecules are also heterodimers, but in this 
case consist of two homogenous peptides, an α and β chain, both of which are 
encoded in the MHC. Unlike HLA-I, the HLA-II molecules are found only on 
antigen-presenting cells (APC) and lymphocytes [149] (figure 14). 
Peptides, generated mainly from degradation of cytosolic proteins processing by 
the proteosome, are transported by transporters associated with antigen 
processing (TAP) 1 and 2 through the endoplasmic reticulum and Golgi apparatus 
to the cell surface. During this process they are complexed to β2m, arriving at the 
cell surface as an HLA class I antigen. 
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This peptide-HLA complex then becomes a target for cytotoxic T-cells. [150, 151]. 
There are many variant alleles of HLA-A, but just A*03 and A*11 hallotypes bind 
KIRs: both of them recognize and bind KIR3DL2, and A*11 can bind KIR2DS4 too 
[126, 152, 153]. 
HLA-B alleles can be divided into two groups based on the presence of a Bw4 or 
Bw6 motif in the α1 domain at residue 77-83 of the molecule. The unique KIR that 
binds with HLA-B is KIR3DL1, recognizing the HLA-Bw4 group [126, 154]. 
HLA-C alleles can be divided into two groups: the C1 group, having a serine (S) at 
residue 77 and an asparagine (N) at residue 80, and C2 group, having an 
asparigine (N) at residue 77 and a lysine (K) at residue 80. KIR2DL1 and 2DS1 
interact with HLA-C2, while KIR2DL2, 2DL3 and 2DS2 with HLA-C1. The C 
specificity is due to a single substitution at 44 residue of KIR2D. KIR2DS4 interacts 
with both HLA-C1 and –C2, as well as with HLA-A11. [126, 152, 153]. All the 
known interaction between HLA and KIR, with their Ig-like domains, are 
summirezed in table 1. 
 
 
KIR Ig-like domains Ligand 
2DL1 D1-D2 HLA-C2 
2DL2 D1-D2 HLA-C1 
2DL3 D1-D2 HLA-C1 
2DL4 D0-D2 HLA-G 
2DL5A D0-D2 Unknown 
2DL5B D0-D2 Unknown 
2DS1 D1-D2 HLA-C2 
2DS2 D1-D2 HLA-C1 
2DS3 D1-D2 Unknown 
2DS4 D1-D2 HLA-C, HLA-A*11 
2DS5 D1-D2 Unknown 
3DL1 D0-D1-D2 HLA-Bw4 
3DL2 D0-D1-D2 HLA-A*3, HLA-A*11 
3DL3 D0-D1-D2 Unknown 
3DS1 D0-D1-D2 HLA-Bw4 
 
Table 1 - Interaction between KIR receptor and HLA 
 
 
1.3.15 KIR and diseases 
 
KIR genes may predispose to human diseases: association studies have 
highlighted the involvement of various factors including haplotype diversity, 
individual gene expression and HLA ligand diversity. Although many association 
studies are available, at now there is only one functional study demonstrating a 
direct “cause and effect” relationship [155]. Cross-sectional functional studies are 
difficult to perform because of the inability to generate specific antibody tools are 
against KIR. 
KIR and HLA ligand interactions have been shown to be important. Clearance of 
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hepatitis C virus has been observed in individuals that possess homozygous 2DL3 
and HLA-C1 alleles [156]. 
It was hypothesized that NK cells were less inhibited in this combination, as HLA-
C1 alleles, were weaker at inhibiting NK cell function that HLA-C2 alleles. As a 
consequence there was more aggressive NK cell mediated activity against 
hepatitis C virus. Similarly in HIV, individuals with HLA-Bw4 and 3DS1 progressed 
more slowly to AIDS than those without. The mechanism for this involves ligation 
of activating KIR3DS1 by HLA-Bw4 ligands leading to activation and virus 
clearance [157]. To note, this study showed that the presence of KIR3DS1 in 
absence of HLA-Bw4 is associated with a more rapid progression to AIDS. Finally, 
a study performing on patients with nasopharyngeal cancer showed that an 
increasing number of activating KIR seems to correlate with the disease, and that 
the presence of HLA-Cw0401 is protective [158]. 
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CHAPTER II 
 
 
MATERIAL AND METHODS 
 
 
2.1 Subjects 
 
In total, 319 individuals were enrolled in the study; these subjects included 32 cKS 
patients, 20 patients with epidemic Kaposi’s sarcoma, 67 HIV+ healthy subjects 
and 200 HIV- healthy donors. 
For healthy donors, subjects undergone to routinely analysis were enrolled, without 
known diseases at the moment of sampling, HIV negative, and with more than 60 
years, so as to be comparable with patients and to minimize the possibility to have 
“false positivity” (i.e. subjects that may develop KS in the future). 
Signed informed consent, from every subject a sample of whole blood (10 ml), and 
serum (5 ml) were collected. For cKS patients also saliva (about 2 ml) were 
collected. 
 
 
2.2 DNA extraction from whole blood 
 
Genomic and viral DNA was extracted from whole blood samples following the 
phenol-chloroform method. 
 
• Thaw whole blood sample (collected in K3-EDTA tube and stored at -20°C) 
and transferred to a sterile 15 ml tube 
• Add PBS up 15 ml, mix and centrifuge for 10 minutes at 1750 rpm 
• Discard supernatant and repeat washing with PBS 
• Add 1 ml of cell lysis solution (1.64 gr NH4Cl; 0.2 gr KHCO3; 0.0074 gr 
tetrasodium EDTA), mix and wait up 5 minutes 
• Add PBS up 15 ml and centrifuge for 10 minutes at 1750 rpm 
• Discard supernatant 
• Put the pellet in a tube, adding about 1 ml PBS, mix and centrifuge for 10 
minutes at 13000 rpm 
• Discard supernatant, add 500 µl of protein lysis solution and 7.5 µl of 
proteinase K (20 mg/ml) 
• Incubate sample at 57°C for 1 hour 
• Add 800 µl of chloroform, mix and centrifuge for 10 minutes at 10000 rpm 
• Transfer the upper phase (watery phase vs lower and organic phase) in a 
new tube with 100% ethanol 
• Shack by hands till the formation of DNA flocculus 
• Transfer the flocculus in a tube with 70% ethanol, washing and finally 
transfer it in a tube with 50 µl of H2O 
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2.3 DNA extraction from saliva 
 
Genomic and viral DNA extraction from saliva was performed using Oragene DNA 
(DNA Genotek) kits.  
 
• Collect about 2 ml of saliva in Oragene DNA tube (the subject shouldn’t 
have eaten, drunk, smoken or chewed gum for 30 minutes before living 
their saliva sample) 
• Put the tube on a flat surface 
• Screw the cap onto the container, so that oragene solution can mix with 
saliva 
• Mix gently for at least 10 seconds 
• Incubate the sample at 50 °C in a water incubator overnight 
• Transfer the mixed sample to a 1.5 ml to a 15 or 50 ml centrifuge tube 
• Add 1 ml of cell lysis solution and 25 µl Gentra RNase A Solution (4 mg/ml) 
• Vortex at high speed for 10 seconds to mix sample 
• Incubate 10 minutes at room temperature 
• Add 1.67 ml of protein precipitation solution to the cell lysate 
• Vortex vigorously at high speed for 20 second to mix the protein 
precipitation solution uniformly with the cell lysate 
• Incubate the samples on ice for 5 minutes 
• Centrifuge at 2000 g for 5 minutes. The precipitated proteins will form a 
tight dark brown pellet 
• Pour the supernatant containing the DNA (leaving behind the precipitated 
protein pellet) into a 15 or 50 ml tube containing 5 ml of 100% isopropanol 
and 40 µl of Gentra Glycogen Solution (20 mg/ml) 
• Mix the sample by inverting gently 50 times 
• Centrifuge at 2000 g for 3 minutes; the DNA will be visible as a small white 
pellet 
• Pour off supernatant and drain tube briefly on clean absorpent paper. Add 
5 ml of 70% ethanol and invert tube several times to wash DNA pellet 
• Centrifuge at 2000 g for 1 minute. Carefully pour off the ethanol 
• Invert and drain the tube on clean absorpent paper and allow the sample 
to air dry for 5 to 10 minutes 
• Add 400 µl of DNA hydration solution 
 
 
2.4 DNA quantification 
 
The concentration of DNA solution was determined by spectrometer measuring 
DNA absorption at 260 nm wavelength, against blank, according the Lambert-Beer 
law: 
 
A = ε c l 
with: 
 
A = absorption 
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ε = molar absorption coefficient; 
c = concentration 
l = optical path. 
 
The ratio A260/A280 is used to estimate the purity of nucleic acid, since protein 
absorb at 280nm. Generally, for DNA, a good value is between 1.8-2.0: a ratio 
higher than 2.0 indicates that samples may be contaminated with chloroform or 
phenol, whereas a ratio lower than 1.8 indicated that samples may be 
contaminated with proteins. 
 
 
2.5 HHV-8 antibody detection in serum 
 
Antibodies against latent and lytic HHV-8 antigens were separately detected in 
serum samples by using an in-house indirect immunflourescence assay (IFA), 
based on BCLB-1 cell lines. As written in the introduction, these cells are able to 
maintain the viral genome in latent episomic form at nuclear level [43], but it is also 
possible to induce viral replication and the consequent expression of the lytic 
antigens, by treatment with IL-6 and phorbol-12-myristate-13-acetate (TPA). 
 
A cell culture system was prepared to maintain and to expand the cell line: 
 
• Culture BCBL-1 cells in flask with cell culture medium (RPMI 1640, Sigma 
Aldrich, Missouri, USA, with 10% heat fetal bovine serum (FBS), antibiotics 
(100 U/ml penicillin and 100 µg/ml streptomycin) and glutamine (100 
µg/ml) 
• Incubate at 37 °C and 5% CO2. At these growth conditions, the virus is 
present in cells in a latent state and only 5% of the cells are observed in 
active replication 
• To promote also the expression of lytic antigens, add TPA (20 µg/ml, 
Sigma Aldrich) and IL-6 (200 U/ml, Sigma Aldrich) to the cells and wait 72 
hours: at these conditions, about 25-30% of cells show an active viral 
replication. In this way it is possible to study both latent and lytic phase of 
the virus, and consequently, to identify antibodies against latent antigens, 
localized at the nuclear level, and even lytic antigens, localized in the 
cytoplasm and on the viral cell membrane. 
 
IFA allows a qualitative and quantitative assessment of antigen-antibody reaction 
that occurs at level of well-defined target structures such as the nucleus and 
cytoplasm. The method is called indirect because uses a secondary antibody, 
labeled with a fluorochrome, that can recognize the primary antibody-antigen 
complex. In our case, a secondary antibody directed against human IgG, labeled 
with FITC fluorochrome has been used. 
For the fixation and permeabilization, a commercial kit (Fix and Perm, Caltag 
Laboratories, France) has been used. 
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• Wash cells and centrifuged at 1500 rpm for 10' 
• Colour cells with Trypan-blue, count viable cells using a Burker chamber 
• Add 800 µl of fixative to cells 
• Incubate for 15' at dark at room temperature 
• Add 2 ml of PBS to the suspension 
• Wash cells twice by centrifugation at 1500 rpm for 5' 
• Resuspend the pellet with 800 µl of permeabilization buffer 
• Incubated at dark for 20' at room temperature 
• Wash cells twice with 2 ml of PBS 
• Put cells on the slide 
• Dry the slides under a laminar flow hood 
• Put the slides in cold acetone (4 °C) for 10’ 
• So treated, the slides can be stored at -20 °C, protected by light. 
 
This procedure allows the entrance of fluorescein (fluorescein isothiocyanate, 
FITC) and antibodies within the cell (in cytoplasm and even nucleus), leaving intact 
the morphological characteristics. For our assays, 6x104 cells have been deposited 
on each well of one slide. The optimal concentration has been determined by serial 
dilutions of the cell suspension, to have a uniform monolayer of cells in each single 
well. 
 
 
Antibodies detection: 
 
 
• Put on each spot of cells on the slide 10-15 µl of diluted (1:100 with PBS) 
serum sample 
• Incubate in a humid chamber at 37 °C for 1 hour 
• Wash the slides twice in PBS for 10' under agitation to eliminate any non-
specific binding between viral and cellular antigens and serum antibodies 
• Add on each wells 10 µl of FITC-conjugated (FITC-conjugated Anti-Human 
γ-Globulin with Evans Blue, Sigma Aldrich) secondary antibody, directed 
against human immunoglobulins 
• Incubate the slides for 30' at 37 °C to allow the reaction between primary 
antibody and labeled secondary antibody 
• Wash the slides twice in PBS 
• Dry the slides on air 
• Cover the slides with cover slips, helping yourself with glycerol 
• Examine the slides with a fluorescence microscope. 
 
Samples were considered positive for antibodies to latent antigens when about 
80% of BCBL-1 cells in the latent stage had punctiform fluorescence in the nuclear 
level. By contrast, the samples were considered positive for antibodies to lytic 
antigens when 30% of the BCBL-1 cells in lytic stage had a uniform cytoplasmic 
fluorescence. As a further control of specificity, the solution of FITC-labeled 
secondary antibody was tested on the substrate in the absence of human serum, 
while as a positive control serum was used serum from a well-known Kaposi’s 
sarcoma patient. 
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2.6 KIR and HLA genotyping 
 
The PCR (polymerase chain reaction) is a technique that allows the enzymatic 
amplification in vitro of a specific DNA sequence, by using oligonucleotide pairs 
(DNA primer). 
KIR genotyping was performed by SSP-PCR (single specific primer PCR) method, 
a technique based on a sequence-specific primer panels, using “KIR Genotyping” 
BAG plates for the molecular determination of loci. Every plate is formed by 24 
wells with a specific primer pairs for a single allele of each locus, where PCR 
reaction performs. In particular, this kit allows amplifying KIR 2DL1, 2DL2, 2DL3, 
2DL4, 2DL5A, 2DL5B, 2DS1, 2DS2, 2DS3, 2DS4, 3DS1, 3DL1, 3DL2, 3DL3 genes 
and 2DP1 and 3DP1 pseudogenes. 
Similarly, also HLA-A, -B and –C typing was performed by SSP-PCR method, 
using “Hysto Type” BAG plate. 
 
 
This is the protocol for KIR genotyping and HLA typing: 
 
DNA (50 ng/µl)  2 µl 
10 X PCR Buffer 1 µl 
Taq Polymerase (5U/ µl) 0.08 µl 
Sterile H2O 6.92 µl 
Final volume 10 µl 
 
 
These are the amplification conditions for KIR genotyping (phase 1: 10 cycles; 
phase 2: 20 cycles): 
 
 
 Temperature Time 
Polymerase activation 94°C 2’ 
Denaturation 1 94°C 15’’ 
Annealing 1 65°C 50’’ 
Extension 1 72°C 45’’ 
Denaturation 2 94°C 15’’ 
Annealing 2 61°C 50’’ 
Extension 2 72°C 45’’ 
Final extension 72°C 10’ 
Blocking reaction 4°C 10’ 
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These are the amplification condition for HLA typing (phase 1: 5 cycles; phase 2: 
10 cycles; phase 3: 15 cycles): 
 
 
 Temperature Time 
Polymerase activation 96°C 5’ 
Denaturation 1 96°C 20’’ 
Annealing 1 68°C 30’’ 
Extension 1 68°C 30’’ 
Denaturation 2 96°C 20’’ 
Annealing 2 64°C 50’’ 
Extension 2 72°C 45’’ 
Denaturation 3 96°C 20’’ 
Annealing 3 61°C 50’’ 
Extension 3 72°C 45’’ 
Final extension 72°C 10’ 
Blocking reaction 4°C 10’ 
 
 
 
2.7 KIR haplotype and ligands 
 
As written in the introduction, two broad haplotypes, termed A and B, are defined 
based on KIR genes. A and/or B haplotypes were calssified based on the criteria 
adopted by Middleton and colleagues (http://www.allelefrequencies.net) [159]. 
Ligands group was defined as follows: 
 
1- KIRs 2DL1 and 2DS1 bind the C2 epitope (Asparagine at position 77, Lysine at 
position 80). 
2- KIRs 2DL2, 2DL3, and 2DS2 bind the C1 epitope (Serine at position 77, 
Asparagine at position 80). 
3- HLA-Bw4 and the HLA-Bw4*80I (Isoleucine at position 80) subset were 
considered the ligand for KIR 3DL1 and 3DS1) [130, 157]. 
 
 
2.8 Agarose gel electrophoresis 
 
• Mix agarose powder with 1X TBE buffer to obtain a 2% final solution 
• Heat in a microwave oven until gel is completely melted 
• Add ethidium bromide (final concentration 1µl/ml) to allow the DNA 
visualization 
• Pour the solution into a casting tray containing a sample comb 
• Wait till the solidification of gel 
• Remove the comb, using care not to rip the bottom of the wells 
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• Insert the gel into the electrophoretic chamber and just cover with TBE 
buffer 
• Put samples into the wells 
• Turn on the electrophoresis machine 
• Wait till an adequate migration 
• Visualize DNA fragments placing the gel on a ultraviolet transilluminator. 
 
To note, DNA fragments are visualized by staining with ethidium bromide. This 
fluorescent dye intercalates between bases of DNA (and RNA) and allows seeing 
nucleotide when lighted by ultraviolet.  
 
 
2.9 HHV-8 viral load measurement by real-time PCR 
 
Real-time PCR, also called quantitative PCR (qPCR), is a technique based on the 
PCR, which is used to amplify and simultaneously quantify a targeted DNA 
molecule. For one or more specific sequences in a DNA sample, real time PCR 
enables both detection and quantification. The quantity can be either an absolute 
number of copies or a relative amount when normalized to DNA input or additional 
normalizing genes. 
 
HHV-8 viral load was determined by real-time PCR using an ABI PRISM 7000 SDS 
(Applied Biosystem, Foster City, CA). Primers and probe were designed using the 
Primer express software (Applied Biosystem), to obtain a 74 bp amplicon on 
ORF26 region of the viral genome, coding for HHV-8 minor capsid protein. PCR 
amplification was performed in 25 µl reaction mixture using Taqman Universal 
masterMix (Applied Biosystem), 0.9 mM each primers, 0.2 mM Taqman probe and 
500 ng of blood DNA or 10 µl of DNA extracted from saliva were used as template. 
Each sample was analyzed in triplicate: samples that did not yield three positive 
reactions were repeatedin triplicate and viral load results were given by the mean 
of the three positive reactions. Each run contained a negative control, constituted 
by the reaction mixture without the DNA template. Viral load was analyzed by 
interpolation of a standard curve obtained from serial dilution of HHV-8 quantified 
purified viral DNA (Advanced Biotechnologies Inc, Columbia, MD). The assay was 
linear from 101 to 107 copies per reaction. The interassay variability, evaluated by 
repeating the quantitation of the same positive specimen for 8 times, was low, with 
the coefficient of variation less than 20% for viral load ranging from 130 copies/ml 
(2.11 log10) to 1.3x105 copies/ml (5.11 log10). The specificity was tested using as 
template DNA of EBV (whose genome is very similar to HHV-8 genome), which 
was not amplified. The lowest detection limit was 10 copies/reaction, which is 
equivalent to 40 copies/µg of DNA extracted from blood and 4000 copies/ml of 
saliva. 
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Amplification conditions (40 cycles): 
 
 
 Temperature Time 
Amperase UNG activation 
(inside Taqman master mix) 50°C 2’ 
Polymerase activation 95°C 15’’ 
Annealing 60°C 30’’ 
Extension 60°C 30’’ 
Blocking reaction 4°C 10’ 
 
 
Sequences of primers and probe, studied for the ORF26 region of the viral 
genome, are: 
 
 
 Position Sequence Tm 
ORF26F 
Forward 
primer 
47311-
47331 
5’- CTC GAA TCC AAC 
GGA TTT GAC -3’ 52.2 °C 
ORF26R 
Reverse 
primer 
47385-
47366 
5’- TGC TGC AGA ATA 
GCG TGC -3’ 53.1 °C 
Probe 47342-47360 
6 FAM-CCA TGG TCG TGC 
CGC AGC A-TAMRA 57.4 °C 
 
with: 
 
Tm = melting temperature. 
The position is referred to accession number: U75698. 
 
 
The lowest detection limit was 10 copies per reaction, which was equivalent to 40 
copies (µg DNA extracted from blood)-1 or 630 copies (ml saliva)-1. 
The real time PCR was performed using an ABI Prism 7000 sequence detection 
system (Applied Biosystem). 
 
 
2.10 HHV-8 genotyping 
 
Genotype characterization of HHV-8 strains was based on sequencing of variable 
regions VR1 (spanning nt. 46-425), VR2 (spanning nt. 68-817) and VR3 (spanning 
nt. 607-942) of the hypervariable ORF-K1viral gene, coding for a transmembrane 
protein. 
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2.10.1 Nested PCR 
 
Nested PCR is a variation of PCR, in that two pairs (instead of one pair) of PCR 
primers are used to amplify a fragment. The first pair of PCR primers amplifies a 
fragment similar to a standard PCR (outer fragment). However, a second pair of 
primers called nested primers binds inside the first PCR product fragment to allow 
amplification of a second PCR (inner fragment) product, which is shorter than the 
first one. 
 
 
Amplification of the outer fragment (nt. 23-987, 966 bp) 
 
 
DNA  (100 ng/µl) 5 µl 
DMSO 2 µl 
10 X PCR Buffer solution 5 µl 
MgCl solution (50 mM) 2 µl 
dNTPs (10 mm) 3 µl 
Outer forward primer (10 µM) 3 µl 
Outer reverse primer (10 µM) 3 µl 
TaqGold polymerase (5U/µl) 0.3 µl 
Sterile H2O 26.7 µl 
Final volume 50 µl 
 
 
Amplification conditions (30 cycles): 
 
 
 Temperature Time 
Polymerase activation 94°C 10’ 
Denaturation 94°C 30’’ 
Annealing 53°C 45’’ 
Extension 72°C 2’ 
Final extension 72°C 7’ 
Blocking reaction 4°C 10’ 
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The sequences of primers are: 
 
 Position Sequence Tm 
OK1 forward 
primer 23-38 
5’- GTT CTG CCA GGC ATA 
GTC T-3’ 51.0 °C 
OK1 reverse 
primer 987-960 
5’- TCT TAC CTG AAT GTC AGT 
ACC A -3’ 51.2 °C 
 
 
Tm = melting temperature. 
The position is referred to accession number U75698. 
 
 
Amplification of VR1 inner fragment (nt. 46-425, 377 bp) 
 
 
Outer fragment  (100 ng/µl) 5 µl 
DMSO 2 µl 
10 X PCR Buffer solution 5 µl 
MgCl solution (50 mM) 1.5 µl 
dNTPs (10 mm) 2 µl 
Inner forward primer VR1 (10 µM) 2 µl 
Inner reverse primer VR1 (10 µM) 2 µl 
TaqGold polymerase (5U/µl) 0.3 µl 
Sterile H2O 30.2 µl 
Final volume 50 µl 
 
 
Amplification conditions (phase 1: 14 cycles: phase 2: 19 cycles): 
 
 
 Temperature Time 
Polymerase activation 94°C 10’ 
Denaturation 1 94°C 30’’ 
Annealing 1 57°C -0.5°C each cycle 30’’ 
Extension 1 72°C 40’’ 
Denaturation 2 94°C 30’’ 
Annealing 2 50°C 30’’ 
Extension 2 72°C 50’’ 
Final extension 72°C 5’ 
Blocking reaction 4°C 10’ 
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The sequences of primers are: 
 
 Position Sequence Tm 
VR1int 
forward 
primer 
46-65 5’- CTG GGC GGC CCT TGT GTA AAC -3’ 56.0 °C 
VR1int 
reverse 
primer 
425-405 5’- GAC TGT GTT TGA TGG CTG GC -3’ 54.4 °C 
 
 
Tm = melting temperature. 
The position is referred to accession number: U75698. 
 
 
Amplification of VR2 inner fragment (nt. 68-817, 749 bp) 
 
 
Outer fragment  (100 ng/µl) 5 µl 
DMSO 2 µl 
10 X PCR Buffer solution 5 µl 
MgCl solution (50 mM) 1.5 µl 
dNTPs (10 mm) 3 µl 
Inner forward primer VR2 (10 µM) 3 µl 
Inner reverse primer VR2 (10 µM) 3 µl 
TaqGold polymerase (5U/µl) 0.3 µl 
Sterile H2O 27.2 µl 
Final volume 50 µl 
 
 
Amplification conditions (30 cycles): 
 
 
 Temperature Time 
Polymerase activation 94°C 10’ 
Denaturation 94°C 30’’ 
Annealing 54°C 45’’ 
Extension 72°C 2’ 
Final extension 72°C 10’ 
Blocking reaction 4°C 10’ 
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The sequences of primers are: 
 
 
 Position Sequence Tm 
VR2 forward 
primer 68-88 
5’- TCT TTC AGA CCT TGT TGG 
AC -3’ 50.0 °C 
VR2 reverse 
primer 
817-
801 
5’- CAG AGC TAC GAG TGT 
CAT -3’ 48.8 °C 
 
 
Tm = melting temperature. 
The position is referred to accession number: U75698. 
 
 
Amplification of VR3 inner fragment (nt. 607-942, 335 bp) 
 
 
Outer fragment  (100 ng/µl) 5 µl 
10 X PCR Buffer solution 5 µl 
MgCl solution (50 mM) 1.5 µl 
dNTPs (10 mm) 2 µl 
Inner forward primer VR2 (10 µM) 2 µl 
Inner reverse primer VR2 (10 µM) 2 µl 
TaqGold polymerase (5U/µl) 0.3 µl 
Sterile H2O 32.2 µl 
Final volume 50 µl 
 
 
Amplification conditions (phase 1: 14 cycles; phase 2: 19 cycles): 
 
    
 Temperature Time 
Polymerase activation 94°C 10’ 
Denaturation 1 94°C 30’’ 
Annealing 1 63°C -0.5°C each cycle 30’’ 
Extension 1 72°C 50’’ 
Denaturation 2 94°C 30’’ 
Annealing 2 56°C 30’’ 
Extension 2 72°C 40’’ 
Final extension 72°C 5’ 
Blocking reaction 4°C 10’ 
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The sequences of primers are: 
 
 Position Sequence Tm 
VR3 forward 
primer 607-628 
5’- GTA TAT GTT TTT GGG CGC 
GTT G -3’ 53.4 °C 
VR3 reverse 
primer 942-922 
5’- CCG TGC ACA AAT CGT GTA 
GGG -3’ 55.8 °C 
 
 
Tm = melting temperature. 
The position is referred to accession number: U75698. 
 
 
2.10.2 DNA sequence analysis 
 
DNA sequencing is the determination of the precise sequence of nucleotides in a 
sample of DNA. 
 
 
2.10.2.1 Pre-labeling DNA purification 
 
At first, the PCR product was purified to eliminate all contaminants (exceeding 
dNTPs or primers) that could interfere with sequencing reaction. The purification 
was performed by using QIAquick PCR Purification Kit Protocol Kit (Qiagen, 
Valencia, CA, USA). 
 
• Add 5 volumes of Binding Buffer QG to PCR mixture 
• Put the sample in purification column 
• Centrifuge at 13000 rpm for 1 minute 
• Add 500 µl of PE 
• Centrifuge at 13000 rpm for 1 minute 
• Elute the DNA from column with 50 µl of water and centrifuge at 13000 
rpm for 1 minute. 
 
Alternatively, if in the electrophoresis gel multiple lanes were present, the 
purification was performed by using QiAquick Gel Extraction Kit Protocol (Qiagen): 
 
• Cut from gel the lane of the amplification of interest 
• Put the cut gel in a tube 
• Add 300 µl of QG buffer per 100 µg of sample 
• Incubate the sample at 50 °C for 10 minutes, mixing every 2-3 minutes, to 
allow the gel dissolution 
• Add 1 volume of isopropanol 
• Put the sample in a purification column 
• Centrifuge at 13000 rpm for 1 minute 
• Add 500 µl of PE 
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• Centrifuge at 13000 rpm for 1 minute 
• Elute the DNA from column with 50 µl of water and centrifuge at 13000 
rpm for 1 minute. 
 
 
2.10.2.2 Labeling reaction 
 
This step is necessary to incorporate fluorescent didesoxynucleotides, defined 
BigDye terminators into sequencing DNA. The labeling structure contains a 
fluorescein donor (6-FAM) molecule, linked to one of the 4 dichloroamine acceptor. 
The maximum excitation of every labeled is the fluorescein excitation, and the 
emission spectrum is the rhodamine emission spectrum. BigDye terminators are 
labeled with these dRhodamine molecules: 
 
 
• A = dichlorine [R6G]    Green 
• C = dichlorine [ROX]    Blue 
• G = dichlroine [R110]    Black 
• T = dichlorine [TAMRA]    Red 
 
 
For this step, BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystem) 
has been used. 
 
This is the reaction mixture: 
 
DNA (300 ng) x µl 
2.5X Terminator Ready Reaction Mix 4 µl 
Primer (pmol/µl) 3.2 µl 
5X BigDye Sequencing buffer 2 µl 
Sterile H2O (up to 20 µl final volume) x µl 
Final volume 20 µl 
 
 
Adjust the DNA (and H2O) volume to have a concentration of 300 ng. 
 
Amplification conditions (25 cycles): 
 
 
 Temperature Time 
Polymerase activation 96°C 1’ 
Denaturation 96°C 10’’ 
Annealing 50°C 5’’ 
Extension 60°C 4’ 
Blocking reaction 4°C 10’ 
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2.10.2.3 Post-labeling DNA purification 
 
This procedure is necessary to eliminate the Big Dye Terminators excess that 
could interfere with the electrophoretic running and the detection of fluorescence. 
This procedure was performed by using NUCLEOSEP kit (Macherey-Nagel). 
 
 
• Add to the purification column with 800 µl of water 
• Leave the column at room temperature for 2 hours  
• Centrifuge the column at 3800 rpm for 2 minutes 
• Add the sample (2 µl) to the column 
• Centrifuge at 3800 rpm for 2 minutes 
• Collect the flow-through 
 
 
2.10.2.4 DNA sequencing 
 
DNA sequencing has been performed with ABI Prism 310 Genetic Analyzer 
(Applied Biosystem), constituted by a capillary electrophoresis machine, a laser for 
to excite fluorophores, a CCD-camera to detect the signal, and a software to 
elaborate data. The polymer that we used for this electrophoretic experiment is 
POP6 polymer (Invitrogen). For each sample, 5 µl of the purified product has been 
used. 
 
 
2.10.2.5 Sequence analysis 
 
Sequence homology searches were determined by using BLAST. The genotype of 
each sample was determined by comparing its sequence with those of HHV-8 
prototype [58], obtained from GenBank. Multiple sequence alignment was 
performed using the CLUSTAL W version 1.7 program [160]. Genotyping was 
confirmed with amino acidic alignment of the N-terminal VR1 region (aa 1-59), 
analyzing the presence of distinctive residues, as reported previously by Zong et 
al, 1999 [58]. 
 
 
2.11 Statistical analysis 
 
Group data are expressed as mean ± SEM (standard error of mean) or as median 
(range). Differences in frequency were evaluated by means of a χ2 or Fisher’s 
exact test, and Bonferroni correction for multiple tests, as appropriate. All tests 
were two-sided. The association of each polymorphism with disease was 
measured by the Odd Ratio (OR) and a 95 % Confidence Interval (95%CI). For 
each independent variable, crude and adjusted odds ratios and 95 % confidence 
interval were calculated. 
To analyze differences among groups, ANOVA and Student’s t-test were 
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performed for parametric data, and Kruskal-Wallis test and Mann-Whitney U test 
for non-parametric data. For multiple tests, Bonferroni correction test was 
performed. Probability values of p<0.05 were accepted as significant. 
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CHAPTER III 
 
 
RESULTS 
 
 
3.1 Clinical characteristics of study’s subjects 
 
The clinical characteristics of the subjects examined in this study are shown in 
table 2. 
 
 cKS patients Epidemic KS patients 
HIV+ “non KS” 
subjects 
HIV- healthy 
donors 
Total number 32 20 67 200 
Men/women, n 23/9 18/2 44/23 126/74 
Age, yr 71.1±7.7 43.5±9.5 45±8.1 74±11.8 
Slow/Fast 
evolution of KS 14/18 11/9 ---- ---- 
 
Table 2 – Clinical characteristics of study’s subjects 
 
 
Demographic analysis revealed that age was not significantly different between 
cKS patients and HIV- healthy donor, as well as between epidemic KS patients and 
HIV+ healthy subjects, which are the couple to compare. 
The age of cKS patients and HIV- healthy donors was significantly higher than 
epidemic KS patients and HIV- healthy subjects (p<0.05), due to the clinical 
characteristics of cKS, which develops particularly in old age. 
About sex, no significant differences were present among the four groups, as well 
as about KS evolution, based on clinical parameters [161], between cKS patients 
and epidemic KS patients. 
 
 
3.2 HHV-8 seroprevalence 
 
HHV-8 seroprevalence was analyzed by immunofluorescence assay (IFA). As 
expected, all cKS patients (100%) were HHV-8 seropositive. About epidemic KS, 
85.0% of cases (17/20) were seropositive. Among non-KS subjects, 47.8% (32/67) 
of HIV+ healthy subjects, and 9.0% (18/200) of HIV- healthy donors were HHV-8 
seropositive (table 3). 
As expected, all these differences were significant, remarking that the HHV-8 
infection is a risk factor for KS development (p<0.0001 between cKS and healthy 
donors; p=0.003 between epidemic KS and HIV+ healthy subjects). 
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Table 3 describes the clinical characteristics of subjects, divided according the 
presence or absence of anti-HHV-8 antibodies. To note, from this point we used 33 
HIV- HHV-8- healthy donors (from the 182 initially screened for HHV-8 
seropositivity) for all next experiments. 
 
 
 cKS patients 
Epidemic 
KS 
patients 
HIV+ 
HHV8+ 
subjects 
HIV+ 
HHV8- 
subjects 
HIV- 
HHV8+ 
healthy 
donors 
HIV- 
HHV8- 
healthy 
donors 
Total 
number 32 17/20 32 35 18 33 
Men/ 
women, 
n 
23/9 18/2 27/5 17/18 8/10 24/9 
Age, yr 71.1±7.7 43.5±9.5 46.8±9.1 44.3±8.7 83.4±11.6 70.0±12.6 
 
Table 3 – Subdivision of study’s subjects according to HHV-8 seroprevalence 
 
 
Again, no significant differences were observed for age and sex among cKS 
patients, HIV- HHV-8+ and HIV- HHV-8- healthy donors and among epidemic KS, 
HIV+ HHV8+ and HIV+ HHV-8- subjects. 
 
 
3.3 HHV-8 DNA in blood and saliva 
 
The presence of HHV-8 DNA in blood and saliva samples was analyzed in all the 
170 individuals enrolled in the study. The results showed that the viral DNA could 
be detected in biological specimens from all the HHV-8+ groups, even if not in 
every HHV-8+ subjects. Thus, HHV-8 DNA was detected in the blood of 65.6% of 
cKS patients (21/32), in 45% of epidemic KS patients (9/20), in 15.6% (5/32) HIV+ 
HHV-8+ subjects and in 22.2% (4/18) of HIV- HHV-8+ healthy subjects. DNA 
isolation was significantly more frequent in cKS patients and in epidemic KS 
compared to HHV-8+ subjects (p=0.0001 for both). 
As expected, none of HHV-8 seronegative individuals had viral DNA in their 
biological samples. 
Saliva samples were collected only in 27/32 cKS patients. In this case, HHV-8 
DNA was isolated in 44.4 % of cKS patients (12/27). 
The blood viral load of cKS patients was 7.40x103±1.64x103. According to the 
evolution of the disease, we found that the viral load was significantly higher in cKS 
patients with fast progression of the disease (1.12x104±2.46x103) compared to 
slower-progression patients (3.98x103±1.51x103; p=0.02). 
For the other groups, the calculation of viral load has not been possible probably 
cause of the low amount of viral DNA in blood. 
All these results are summarized in table 4. 
 52 
 
3.4 HHV-8 genotyping 
 
Sequence analysis of VR1, VR2 and VR3 variable region of hypervariable ORF-K1 
gene has been possible in 29/32 cKS patients, in 9/20 epidemic KS, in 2/32 HIV+ 
HHV-8+ healthy subjects and in none HIV- HHV-8+ healthy donors. 
Nucleotide analyses of amplified HHV-8 DNA showed the subjects of 14 cases 
with A subtype (in particular 13 with A3 and 1 with A4), and 15 with C subtype (10 
with C1 and 5 with C3) in cKS patients, 5 subjects with A subtypes (all with A1) 
and 4 with C subtypes (3 with C1 and 1 with C3) in epidemic KS patients, and 2 
individuals with C subtypes (all with C3) in HIV+ HHV-8+ healthy subjects (table 4). 
Taken together, the A1 HHV-8 subtype was statistically more frequent in epidemic 
KS patients compared to cKS patients (p=0.0003), whereas the A3 subtype was 
statistically more frequent in cKS (p=0.01). 
No significant difference was found for HHV-8 viral load between cKS patients with 
A HHV-8 subtype (9.77x103±3.22x103) and those with C subtype 
(5.78x104±1.58x103). 
Data obtained from HHV-8 phylogenetic analysis are reported in figure 15, where 
the clustering in A1 subtype for epidemic KS, and in A3 for cKS, is clearly shown. 
 
 
 cKS patients 
Epidemic 
KS 
patients 
HIV+ 
HHV8+ 
subjects 
HIV+ 
HHV8- 
subjects 
HIV- 
HHV8+ 
healthy 
donors 
HIV- 
HHV8- 
healthy 
donors 
Viral DNA 
in blood 65.6 % 45.0 % 15.6 % 0 % --- 0 % 
Viral DNA 
in saliva 44.0 % --- --- --- --- --- 
HHV-8 
genotyping 14A/15C 5A/4C 2C --- 0 % --- 
 
Table 4 – Viral DNA and HHV-8 genotyping in study’s subjects 
 
 
3.5 HHV-8 genotyping and KS evolution 
 
To analyze in more depth the role of HHV-8 genotyping in the disease and, in 
particular, in its fast or slow development, we decided to combine these results 
with previous data with another group of 27 cKS patients, for a total fo 59 cKS 
subjects. 
In this new sub-analysis, 33 cKS patients presented a fast cKS development, 
whereas 26 presented a slow evolution.  
HHV-8 A subtype was observed in 21/33 (63.6%) faster-progressing patients, 
whereas C subtype was present only in 12/33 (36.4%) subjects. In contrast, A 
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subtype was observed only in 6/26 (23.1%) patients with slower disease evolution, 
in whom C subtype was highly prevalent (20/26, 76.9%). These differences were 
statistically significant (p=0.003) (figure 16). 
Due the low number of patients, we could not perform this analysis to epidemic KS 
patients too. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 – Predicted phylogenetic distribution of a 942 bp segment of ORF-K1 
gene amplified from cKS patients, epidemic KS patients and HIV+HHV-8- subjects. 
The radial phylogenetic tree was generated using CLUSLTAL W. Bootstrapping for 
100 replicates is noted as a percentage at major branch points. Bar, 0.1 nucleotide 
substitutions per side. A, B, C and D HHV-8 sutbtypes are also reported. Yellow: 
cKS patients; Orange: epidemic KS patients; Blue: HIV+HHV8+ subjects. 
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Figure 16 – HHV-8 A and C subtypes frequency (%) in cKS patients with fast (in 
red) and slow (in black) evolution. 
 
 
 
 
3.6 KIR and HLA genotyping 
 
KIR gene distribution was evaluated in all the 6 groups studied (cKS patients, 
epidemic KS patients, HIV+ HHV-8+ individuals, HIV+ HHV-8- individuals, HIV- 
HHV-8+ healthy donors and HIV- HHV-8- healthy donors), and was reported in table 
5. 
 
 
 
 
 
 
!"
#!"
$!"
%!"
&!"
'!!"
'" #"
(
")
*+
",
-.
/0
12
"
3-21",4564/22750"
+859",4564/22750"
:"2;<1=,/" >"2;<1=,/"
 55 
KIR 
 
cKS 
 
N (%) 
 
Epidemic 
KS 
N (%) 
HIV+ 
HHV8+ 
subjects 
N (%) 
HIV+ 
HHV8- 
subjects 
N (%) 
HIV- 
HHV8+ 
subjects 
N (%) 
HIV- 
HHV8- 
subjects 
N (%) 
Activating KIR       
2DL4 32 (100) 
20 
(100) 
32 
(100) 
35 
(100) 
18 
(100) 
32 
(97.0) 
2DS1 21 (65.6) 
7 
(35.0) 
10 
(31.2) 
10 
(28.6) 
6 
(33.3) 
11 
(33.3) 
2DS2 27 (84.4) 
18 
(90.0) 
17 
(53.1) 
17 
(48.6) 
13 
(72.2) 
18 
(54.5) 
2DS3 18 (56.3) 
7 
(35.0) 
11 
(34.4) 
10 
(28.6) 
5 
(27.8) 
10 
(30.3) 
2DS4*001/2 7 (21.9) 
1 
(5.0) 
11 
(34.4) 
12 
(34.3) 
3 
(16.6) 
2 
(6.1) 
2DS4*003/7 25 (78.1) 
18 
(90.0) 
27 
(84.7) 
28 
(80.0) 
14 
(78.7) 
30 
(90.9) 
2DS5 14 (43.8) 
6 
(30.0) 
5 
(15.6) 
9 
(25.6) 
4 
(22.2) 
7 
(21.2) 
3DS1 20 (62.5) 
5 
(25.0) 
10 
(31.2) 
9 
(25.6) 
5 
(27.8) 
10 
(30.3) 
Inhibitory KIR       
2DL1 32 (100) 
19 
(95.0) 
30 
(93.7) 
33 
(94.3) 
18 
(100) 
33 
(100) 
2DL2 22 (68.8) 
16 
(80.0) 18 (56.2) 
17 
(48.6) 
10 
(55.5) 
18 
(54.5) 
2DL3 28 (87.5) 
17 
(85.0) 
22 
(68.7) 
27 
(77.1) 
18 
(100) 
30 
(90.9) 
2DL5A 12 (37.5) 5 (25.0) 
10 
(31.2) 
12 
(34.3) 
2 
(11.1) 
10 
(30.3) 
2DL5B 7 (21.9) 
7 
(35.0) 
11 
(34.4) 
14 
(40.0) 
2 
(11.1) 
5 
(12.5) 
3DL1 32 (100) 
17 
(85.0) 
31 
(96.8) 
34 
(97.1) 
17 
(94.4) 
33 
(100) 
3DL2 32 (100) 
20 
(100) 
32 
(100) 
34 
(97.1) 
18 
(100) 
32 
(100) 
3DL3 32 (100) 20 (100) 
32 
(100) 
35 
(100) 
18 
(100) 
32 
(97.0) 
Pseudogenes       
2DP1 32 (100) 
19 
(95.0) 
30 
(93.7) 
33 
(94.3) 
18 
(100) 
33 
(100) 
3DP1*001/2/4 0 (0) 
1 
(5.0) 
2 
(6.2) 
2 
(5.7) 
0 
(0) 
0 
(0) 
3DP1*003 32 (100) 
19 
(95.0) 
28 
(87.5) 
31 
(88.6) 
18 
(100) 
33 
(100) 
 
Table 5 – KIR gene distribution in study’s subjects 
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In general, we found some activating KIRs significantly more frequent in KS 
patients compared to healthy subjects. In particular, KIR2DS2 was more frequent 
in both cKS and epidemic KS compared non-KS subjects, whereas KIR2DS1 and 
KIR3DS1 were more frequent in cKS compared healthy individuals. To note, 
KIR2DS4*001/2 allele seems to be less frequent in epidemic KS patients 
compared to their appropriate control groups, even if the difference did not reach 
the level of statistical significance. 
 
Specifically, the results that we obtained were: 
 
2DS1 
 
cKS vs HIV- HHV-8+ subjects: p=0.01; OR: 4.20, 95%CI: 1.5-11.9 
cKS vs HIV- HHV-8- subjects: p=0.02; OR: 3.82, 95%CI: 1.2-12.3 
 
 
2DS2 
 
cKS vs HIV- HHV-8- subjects: p=0.02; OR: 4.50, 95%CI: 1.2-17.4 
epidemic KS vs HIV+ HHV-8+ subjects: p=0.007; OR: 7.94, 95%CI: 1.5-40.0 
epidemic KS vs HIV+ HHV-8- subjects: p=0.003; OR: 9.53, 95%CI: 1.9-47.4 
epidemic KS vs HIV- HHV-8- subjects: p=0.01; OR: 7.50, 95%CI: 1.5-37.7 
 
 
3DS1 
 
cKS vs HIV- HHV-8+ subjects: p=0.04; OR: 4.33, 95%CI: 1.1-18.6 
cKS vs HIV+ HHV-8+ subjects: p=0.02; OR: 3.83, 95%CI: 1.2-12.4 
 
 
No significant differences were observed about inhibitory KIRs, as well as the KIR 
genotype (AA or AB) among the six groups. 
 
Considering overall all data of KIRs, cKS patients showed a significant higher 
frequency of activating KIR genes compared to subjects without the disease, 
regardless the infection with HHV-8 (p=0.01) (figure 17, panel A). 
Similarly, epidemic KS patients had more activiating KIR genes compared to their 
appropriate control groups (p=0.03) (figure 17, panel B). 
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The HLA-B and -C distribution is reported in table 6. No significant differences 
were observed among the groups. 
 
 
HLA cKS Epidemic KS 
HIV+ 
HHV8+ 
subjects 
HIV+ 
HHV8- 
subjects 
HIV- 
HHV8+ 
subjects 
HIV- 
HHV8- 
subjects 
HLA-B       
Bw4 18/32 15/20 16/32 25/35 13/18 19/33 
Bw6 27/32 14/20 26/32 27/35 8/18 25/33 
HLA-C       
C1 
group 22/32 14/20 22/32 29/35 11/18 26/33 
C2 
group 26/32 16/20 24/32 22/35 15/18 24/33 
 
Table 6 – HLA-B and -C gene distribution in study’s subjects 
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Figure 17 – panel A: activating KIR distribution in cKS patients, in HIV- HHV-8+ 
healthy subjects and in HIV- HHV-8- healthy donors (HD). p=0.01. 
Panel B: activating KIR distribution in epidemic KS, in HIV+HHV-8- subjects, in 
HIV+HHV-8+ subjects and in HIV-HHV-8- healthy donors (HD). p=0.03. 
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3.7 KIR and HLA complexes 
 
Since KIR and HLA are strictly linked, as written in introduction, 1.3.14 paragraph, 
we decided to combine their data to verify if there are differences among the 
groups. 
 
3.7.1 KIR/HLA complexes in classic Kaposi’s sarcoma 
 
Evaluations focusing on KIR/HLA complexes showed the presence of higher of 
activating KIR/HLA receptor/ligand genotyping in cKS patients compared to 
subjects without the disease (p=0.01) (figure 18, panel A). 
Taken KIR/HLA complex one by one, a higher frequency of KIR2DS1+/C2+ 
genotypes was detected in cKS compared to HIV- HHV-8+ individuals (p=0.01; OR: 
4.25) and to HIV- HHV-8- healthy donors (p=0.009; OR: 5.37). The association 
between KIR2DS1+/C2+ genotype and cKS was confirmed after binary logistic 
regression analysis adjusted for age and gender (p=0.004; OR: 2.95; 95%IC: 1.42-
6.15, and p=0.003; OR: 3.02; 95%IC: 1.48-6.78 respectively). 
Because HLA-Bw4 molecules are ligands of KIR3DL1 and KIR3DS1, particularly 
Bw4*80I (bearing an Isoleucine at position 80) showed a stronger binding affinity 
with KIR3D alleles, therefore both KIR3DS1+/Bw4+ and KIR3DS1+/Bw4*80I+ 
genotype distributions were analyzed. However, the frequency of KIR3DS1+/Bw4+ 
as well as KIR3DS1+/Bw4*80I+ genotypes in cKS compared to healthy subjects did 
not reach the statistical significance. Conversely, KIR3DS1+/Bw4- frequency 
resulted still statistically higher in cKS than in controls (p=0.006; OR: 6.00), 
confirming that the KIR3DS1 positivity, but not the KIR/HLA receptor/ligand 
combination 3DS1/Bw4*80I, was associated to cKS. 
Finally, no differences were found among the three groups about frequency of 
KIR2DS2+/C1+. All these data are summarized in figure 19, panel A. 
 
 
3.7.2 KIR/HLA complexes in epidemic Kaposi’s sarcoma 
 
Similarly as cKS, also epidemic KS patients had more activating KIR genes and 
activating KIR/HLA receptor/ligand compared to their appropriate control groups 
(p=0.03) (figure 18, panel B). 
As already written (3.6 paragraph), a higher frequency of KIR2DS2+ genotype was 
detected in epidemic KS compared to all the other appropriate control groups. 
However, no significant differences were found for KIR2DS2+/C1 genotypes 
among the groups. 
The HLA ligand of KIR2DS4*001/2 is not known yet, and so for this specific 
activating KIR we could not perform the KIR-HLA complex frequency analysis 
among the groups. 
Finally, the analysis of activating/inhibitory KIR genotypes evidenced that the 
homozygous KIR2DS2+/2DL2- pattern was present in 3/20 epidemic KS patients, 
but in none of 32 HIV+ HHV-8+ (p=0.05) or of 35 HIV+ HHV-8- subjects (p=0.04). All 
these data are summarized in figure 19, panel B. 
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Figure 18 – panel A: activating KIR/HLA complex distribution in cKS patients, in 
HHV-8+HIV- healthy subjects and in HHV-8-HIV- healthy donors (HD). p=0.01. 
Panel B: activating KIR/HLA complex distribution in epidemic KS, in HIV+HHV-8- 
subjects, in HIV+HHV-8+ subjects and in HIV-HHV-8- healthy donors (HD). p=0.03. 
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Figure 19 – panel A: Distribution of specific activating KIR/HLA complex in cKS 
patients, in HHV-8+ HIV- healthy subjects and in HHV-8- HIV- healthy donors (HD). 
Panel B: Distribution of specific activating KIR/HLA complex in epidemic KS, in 
HIV+HHV-8- subjects, in HIV+HHV-8+ subjects and in HIV-HHV-8- healthy 
donors (HD). 
 
 
 
 62 
CHAPTER IV 
 
 
DISCUSSION 
 
 
Kaposi’s sarcoma is a multifocal angioproliferative disorder of vascular 
endothelium, primarily affecting mucocutaneous tissues with the potential to 
involve viscera. Four clinical variants are described for the disease: classic, 
endemic, epidemic (or AIDS-associated), and iatrogenic KS, each with its own 
natural history, site of predilection, and prognosis. In absence of therapy, the 
clinical course of KS varies from innocuous lesions seen in the classic form to 
rapidly progressive and fatal lesions of epidemic KS. 
Human herpesvirus 8 (HHV-8 or Kaposi’s sarcoma associated herpesvirus – 
KSHV) is a recent member of the Herpesviridae family (Gammaherpesvirinae 
subfamily, Rhadinovirus genus), etiologically associated with all variants of KS. 
 
Together with other co-factors not yet clearly defined - probably immune 
dysfunction, route of transmission, environment, host genetic background - HHV-8 
infection is necessary for the development of KS. 
Few studies have assessed the association of HHV-8 viral parameters and KS 
progression, and the majority of these were focalized in HIV-infected patients [162, 
163]. For these reasons, in the first part of this study, immuno-virological analyses 
were performed in 170 KS subjects, divided in cKS patients, iatrogenic KS 
patients, HIV+HHV-8+ or HIV+HHV-8- subjects, and HIV-HHV-8+ or HIV-HHV-8- 
healthy individuals, to verify whether there are any association between these viral 
parameters and the disease. 
HHV-8 antibodies were detected in all cKS patients and in 80% of epidemic KS 
subjects. These data are consistent with those already present in literature: 
although the immunofluorescence assay for detection of antibodies against HHV-8 
latent nuclear antigen (LANA) is considered highly specific [164, 165], it is note that 
in immuno-compromised patients (as epidemic KS subjects), the LANA 
seroreactivity depends on CD4+ lymphocytes, and that in patients with T cells 
lower than 100 per mm3, common in epidemic KS, the seroreactivity could not 
appear [166]. Also the number of HHV-8 seropositive subjects in HIV+ individuals 
(about 50%) and in HIV- healthy donors (about 10%) is very similar to the data 
already present in literature regarding Italy [24, 29, 165, 167]. 
 
Sequence analysis of the HHV-8 highly variable ORF-K1 region has allowed the 
identification of four main HHV-8 subtypes (A, B, C, D) [168], that are differently 
distributed in the world: HHV-8 A and C subtypes predominate in Europe and in 
the United States, B subtype predominates in Africa, whereas D subtype is present 
almost in the Pacific islands only. It is still unclear whether different genotypes are 
associated with diverse rates of disease progression; similarly, the role of viral load 
and other possible surrogate markers on the outcome of KS is still under 
discussion. 
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In this study, HHV-8 nucleotidic sequence has been detected in blood sample of 
65.6% of cKS patients and in 45.0% of epidemic KS patients, a result that confirms 
previous data [163, 169]. 
HHV-8 A and C subtypes predominate in Italy [163, 170], and also our subjects 
had only these kinds of HHV-8 subtypes. Interestingly, the dominant HHV-8 
genotype was different in fast compared to slow progressing patients: A subtype 
was more frequently isolated in patients with fast progression (63.6% vs 36.4%), 
whereas C subtype in individuals with slow progression (76.9% vs 23.1%). HHV-8 
A genotype has been associated with higher transforming potential and higher 
aggressiveness of KS [171-173], even if possible correlations between genotype 
and HHV-8-related pathologies with a different degree of aggressiveness have not 
confirmed by all authors [170, 174, 175]. Our results support the claim that 
infection with HHV-8 A subtype is indeed associated with worst clinical parameters, 
including faster disease. 
Additional results showed that HHV-8 viral load was not detectible in non-KS HHV-
8+ individuals, and that it was significantly increased in cKS patients with more 
severe disease. This is the first time that an association between the evolution of 
the cKS and HHV-8 viral load has been shown: at now this link has been 
demonstrated for epidemic KS only [176]. However we can not exclude that this 
association is caused by HHV-8 subtype: a recent study showed that the A 
genotype is correlated with a higher viral load [177], and, in this study, we found 
that the majority of cKS faster evolution patients had the A HHV-8 subtype. 
Actually, when we analyzed the viral load in A HHV-8 subtype patients compared 
to C HHV-8 subtype patients, the A subtype subjects seem to have a trend for an 
higher viral load, even if this difference did not reach the statistical difference, 
probably due to the low number of subjects. A new study with more patients is 
needed to better understand this relation. However, if confirmed, it is a very 
important aspect, because in this way we would be able to prefigure a possible 
development of the cKS just based on HHV-8 genotyping, and it may allow to 
physicians to prescribe the best drug therapy already in the early stages of the 
disease. 
About HHV-8 genotyping, we also observed that, in the A subtype, patients with 
the classic form of Kaposi’s sarcoma were mainly grouped in A3 subtype, whereas 
patients with the epidemic form were mainly grouped in A1. In literature there is 
just a work that studied the HHV-8 genotyping in Italian patients with epidemic 
Kaposi’s sarcoma, and it did not find any differences regarding the ORF-K1 region 
[178].  However, it needs to underline that in both works the ORF-K1 genotyping 
was performed only for a very small number of patients with epidemic Kaposi’s 
sarcoma: in this work for just 9 patients, and in that paper for two individuals only 
(for one the HHV-8 genotyping was A4, for the other one C3) [178]. So, it is 
possible that this difference in HHV-8 genotyping between classic and epidemic 
Kaposi’s sarcoma is just an artifact, due to the small number of subjects. A new 
work, focalized on ORF-K1 genotyping in epidemic form of Kaposi’s sarcoma only, 
is necessary to verify if this relation between disease and A1 subtype of HHV-8 is 
true or not. 
 
Although it is certain that HHV-8 infection plays a prominent role on the 
progression of KS from an angio-proliferative disorder to sarcoma, HHV-8 infection 
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is nevertheless not sufficient to cause such progression, as not all HHV-8-infected 
individuals develop the disease. The ability to kill virus-infected cells early in the 
immune response (the innate immune response) suggests that there may be a role 
for natural killer cells in determination of the course of HHV-8 infections [179]. The 
activity of natural killer cells is partially regulated by the balance between inhibitory 
and activating signals transmitted by a particular family of receptors. These 
receptors are located at the surface of the natural killer cell and are called killer cell 
immunoglobulin-like receptors (KIR). Carrying more activating KIR genes has been 
associated with a stronger immune response and it has been demonstrated that it 
is related with an increased risk for tumor development as well as for autoimmune 
diseases, such as psoriasis or rheumatoid arthritis [180-183]. KIR gene receptors 
have the capacity to recognize the human leukocyte antigen (HLA) class I 
molecules on target cells [184, 185]. When the expression of certain HLA 
molecules is downregulated by viral infections or cellular transformation, the KIR 
and HLA engagement will be altered. Cells that lack expression of self HLA 
molecules may be destroyed by cytolytic activity of natural killer cells. Moreover, 
when HLA molecules bind activating KIR receptors, a potent inflammatory 
response finalized at NK cell-mediated destruction of target cells, including 
transformed tumor cells and virus-infected cells, is stimulated [186]. KIR and HLA 
loci are highly polymorphic and map in distinct human chromosome (chromosomes 
19 and 6, respectively); both KIR and the specific HLA ligands must be present in 
order to regulate NK cell activity, such that one without the other is functionally 
inert. 
For all these reasons, we investigated whether specific KIR genes and their class I 
ligand were associated with classic Kaposi’s sarcoma or epidemic Kaposi’s 
sarcoma. Results herein, albeit stemming from analyses performed in a limited 
number of individuals, indicate that a statistically higher frequency of activating KIR 
genes together with their HLA ligands is present in HHV-8-infected patients with 
cKS or epidemic KS compared to non-KS patients, regardless of the presence or 
absence of HHV-8 or HIV infection. 
Importantly, whereas activating KIR genes were more frequent in KS patients (both 
cKS and epidemic KS), compared to non-KS subjects, the distribution of KIR 
genes was similar between HHV8+ or HHV8- subjects. Considering the activating 
KIR one by one, the KIR2DS2 gene was prevalent in both cKS and epidemic KS, 
whereas KIR2DS1 and KIR3DS1 were more prevalent in cKS; the similarity of 
KIR2DS1 and KIR3DS1 distribution may be secondary to the fact that these two 
genes are in linkage disequilibrium. No difference was found regarding inhibitory 
KIR in all the analyzed groups. Moreover, considering the KIR/HLA complex, we 
found that the activating KIR2DS1/C2 genotype was positively associated with cKS 
development, whereas the HLA ligand distribution did not reveal any statistical 
association with cKS. This observation, together with the fact that the OR of 
KIR2DS1 association increased when the KIR2DS1/C2 genotype was evaluated, 
may suggest that the association with the disease of KIR2DS1/C2 with cKS is 
mostly due to KIR-HLA interaction and not either KIR or to HLA genes separately.  
Data herein indicate that a KIR/HLA “activating milieu” is present in cKS and 
epidemic KS; such milieu may be a risk factor for the development of this tumor. 
Our results add KS to the list of virus-associated cancers including cervical 
neoplasias and nasopharyngeal carcinoma [158, 187, 188], where an increased 
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presence of activating KIR/HLA receptor/ligand combinations is observed and is 
suggested to play a role in oncogenesis. 
Recent studies have shown that genotypes that increase the activation of NK cells 
are possibly beneficial in viral infection [189]. For example, a study performed on 
HIV positive subjects found that the combination of KIR3DS1 with its ligand HLA-B 
Bw4 80-I was associated with slower progression to AIDS, lower mean viral load, 
and protection against opportunistic infections [157,190]. Moreover, another work 
demonstrated that NK cells expressing KIR3DS1 strongly and significantly inhibited 
HIV-1 replication in cells expressing HLA-B Bw4 80-I as compared to NK cells that 
do not express KIR3DS1, providing the first functional support for the influence of 
KIR3DL1/S1 and Bw4 80-I on anti-HIV NK activity [191]. KIR3DS1 positive NK 
cells clones were preferentially activated by HIV-1 infected target cells, expressing 
HLA-B Bw4 80-I, resulting in lysis of these cells, indicating that NK cells identify 
HIV infected cells actively through KIR3DS1 and Bw4 80-I interaction. 
But in cancer, expecially if inflammation is a major component of tumor 
pathogenesis, and in which is strongly associated with progression of the disease, 
the condition seems opposite. For example, about virus-driven cancer, a recent 
work showed that strongly inhibitory KIR-HLA genotype were protective against 
cervical neoplasias, so that NK cells activation may contribute to a chronic 
inflammatory state in response to human papilloma virus (HPV), the causative 
agent of cervical cancer, setting the stage for carcinogenesis [154]. Moreover, an 
increased number of activating KIR was also found to be associated with 
nasopharyngeal carcinoma, a cancer that is strongly associated with EBV infection 
[158]. 
Our data are in line with this second hypothesis, in which the elicitation of 
inflammation and NK cells activity via KIR/HLA interactions might be directly 
involved in malignant transformation and tumor progression as a consequence of 
the production of cytokines such as TNF-α, IL-6 and TGF-β that contribute to the 
proliferation and survival of tumor cells [192]. Non-specific inflammatory 
responses, such as oxidative DNA damage, may be triggered by activated NK 
upon KIR/HLA interaction as well, possibly facilitating the growth of oncogenic 
viruses [154]. 
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CHAPTER V 
 
 
CONCLUSIONS 
 
Kaposi's sarcoma (KS) is a multifocal vascular neoplasm involving the skin, 
visceral organs and lymph nodes. The lesions are complex and contain distinctive 
proliferating cells with fusiform morphology, called spindle cells, activated 
endothelial cells and infiltrating inflammatory cells. Four clinical variants are 
described for the disease: classic (cKS), endemic, epidemic or AIDS-associated, 
and iatrogenic KS, each with its own natural history, site of predilection, and 
prognosis. 
The link between human herpesvirus 8 (HHV-8 or KSHV) and Kaposi’s sarcoma 
has been proven, but many important aspects including risk factors, genetic 
predisposition to tumor development, transmission of HHV-8, and the pathogenic 
potential of different genotyping remain to be elucidated. 
In the first part of this thesis we decided to verify if there is association between 
HHV-8 viral parameters and KS type and progression, in classic and epidemic 
Kaposi’s sarcoma. 
Confirming the literature, in this study we found that the risk of Kaposi’s sarcoma is 
related with HHV-8 seropositivity: all cKS patients and the 85% of epidemic KS 
patients had HHV-8 antibody in their serum, whereas about half of HIV+ subjects 
(risk category) and 9% of healthy donors had them. 
According to HHV-8 genotyping, this study showed that in cKS, A genotype was 
more frequently isolated in patients with fast progression (63.6%), whereas C 
subtype was more frequent isolated in individuals with slow progression (76.9%). 
The A subtype seems to have a trend for a higher viral load, although this 
difference did not reach a statistical difference. Moreover, among the A subtype, 
patients with the classic form of Kaposi’s sarcoma are mainly grouped in A3 
subtype, whereas patients with the epidemic form are mainly grouped in A1. 
The number of KS patients in which the HHV-8 genotyping was available is not 
very high, so new studies focalized in particular on the genotyping of HHV-8 in a 
large population of cKS and epidemic KS, in every stage’s disease, are needed to 
confirm these data, and the possible role of A subtype in a more aggressiveness of 
the disease. 
 
Even if the role of HHV-8 in the pathology is demonstrated and the virus is 
necessary to develop the disease, HHV-8 infection is nevertheless not sufficient to 
cause the progression of KS from an angio-proliferative disorder to sarcoma, as 
not all HHV-8-infected individuals develop KS. Natural killer cells are central 
components of the innate immune response, and their major role is the protection 
against viral infection and tumor growth via direct and indirect mechanisms. The 
modulation of natural killer activity is a complex and multi factorial phenomenon 
triggered by the binding of inhibitory or activating killer cell immunoglobulin-like 
receptor (KIR) to class I human leukocyte antigen (HLA). For this reason, in the 
second part of this thesis we decided to verify if there is a different distribution of 
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KIR and HLA-B and HLA-C genes in patients with classic and epidemic Kaposi’s 
sarcoma compared to the appropriate control groups. 
We found that patients with cKS and epidemic KS had a statistically higher 
frequency of activating KIR genes compared to non-KS patients. The presence of 
HIV infections, as well as HHV-8 infection, did not correlate with any KIR 
distribution and frequency in subjects without KS. Considering the activating KIR 
one by one, we found that KIR2DS2 gene was more frequent in cKS, as well as in 
epidemic Kaposi’s sarcoma compared to non-KS individuals, whereas KIR2DS1 
and KIR3DS1 were more prevalent in cKS patients compared to non-KS healthy 
donors. Regarding the HLA distribution alone, no differences were found among 
the analyzed groups. About the KIR/HLA complexes, we found that the activating 
complexes were more frequent in cKS and epidemic KS patients compared to non-
KS individuals; moreover, considering KIR/HLA complexes one by one, the study 
showed that the activating KIR2DS1/C2 genotype was positively associated with 
cKS development. 
Results herein indicate that a statistically higher frequency of activating KIR genes, 
as well as KIR/HLA complexes is present in cKS and epidemic KS patients 
compared to non-KS individuals, regardless the presence or absence of HHV-8 or 
HIV infection. 
In the future, it will be important to expand the analysis on HLA-A, another HLA 
ligand for KIR genes, to complete the study on KIR/HLA complex, and to include 
patients with the epidemic and iatrogen form of KS, to verify if also in these two 
different kinds of KS an “activating milieu” compared to the normal population is 
present. 
In conclusion, although these data stem from analyses performed in a relatively 
small group of individuals and will need to be validated using bigger cohorts of KS 
patients, this study shows that KS development is related with a higher frequency 
of activating KIR, as well as of activating KIR/HLA complexes, and that the A 
genotype of HHV-8 is associated with worst clinical parameters of KS, including 
faster disease. 
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